



CareOregon

**Medicaid Prior Authorization Criteria
Last Revised 8/2017**

Important:

Medical policies:

- are not the same as medical advice and do not guarantee any results or outcomes or coverage. If you are a member, please talk about any health care questions with your health care provider.
- do not determine benefits. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied.
- are interpreted and applied at the sole discretion of the Plan, and are subject to state and federal laws.
- explain when certain medical services are medically necessary and whether or not they are investigational (new). For more information about medical necessity and investigational (research) criteria, please see these specific policies. Our coverage guidelines are written to cover a given condition for the majority of people. Each individual's unique, clinical circumstances may be considered.
- are based on constantly changing medical science. We reserve the right to review and update our policies periodically.

Generic Name: Abatacept

Brand Name: Orencia

Revised: 12/24/09, 1/4/11, 3/13/12, 7/13/12, 9/27/12, 9/12/13, 11/12/15

*****Nonformulary for outpatient benefit. PA required on medical benefit.*****

Rheumatoid Arthritis:

Initial Criteria:

1. Has the treatment been prescribed by or is it currently being supervised by a rheumatologist?
If yes, continue to #2. If no, do not approve.
2. Does the member have moderately to severely active rheumatoid arthritis?
If yes, continue to #3. If no, do not approve.
3. Does the member have a history of COPD?
If yes, do not approve. If no, continue to #4.
4. Has the member failed a 4 month trial of ALL of the following biologic DMARDs: Enbrel and Humira?
If yes, continue to #5. If no, do not approve
5. Is Orencia being prescribed along with methotrexate or another non-biologic DMARD (leflunomide, hydroxychloroquine, minocycline, penicillamine, sulfasalazine, aurothioglucose, or auranofin)?
If yes, approve x 12 months: If no, do not approve

Rheumatoid Arthritis:

Renewal Criteria:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count or increase in function?
If yes, continue to #2. If no, do not approve.
2. Approve x 12 months.

Juvenile Idiopathic Arthritis (JIA)

Initial Criteria:

1. Is the member 6 years or older?
If yes, continue to #2. If no, do not approve.

2. Has the treatment been prescribed by or is it currently being supervised by a rheumatologist?
If yes, continue to #3. If no, do not approve.
3. Does the member have moderately to severely active juvenile idiopathic arthritis?
If yes, continue to #4. If no, do not approve.
4. Has the member failed at least a 4 month trial of Enbrel and Humira?
If yes, continue to #5. If no, do not approve
5. Approve x 12 months.

JIA:

Renewal Criteria:

1. Has the member experienced a 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability?
If yes, continue to #2. If no, do not approve.
2. Approve x 12 months.

8. Does the member have HIV co-infection and is NOT currently receiving HAART (antiretroviral) therapy?

If yes, approve x 6 months.

If no, continue to #9

9. Is the member nucleoside/nucleotide-naïve (has not been treated with any CHB therapy including tenofovir, entecavir or telbivudine)?

If yes, do not approve and recommend tenofovir as the preferred formulary alternative.

If no, continue to #10.

10. Approve for 24 weeks (6 months).

Renewal Criteria:

1. Does the member have evidence of treatment compliance evidenced by consistent monthly prescription fills?

If yes, continue to #2.

If no, fwd to RPh

2. Does the member have undetectable HBV DNA?

If yes, approve for 12 months.

If no, fwd to RPh

Generic Name Aflibercept

Brand Name Eylea

Created: 3/13/12

Reviewed: 9/13/12, 9/12/13, 11/13/2014

Updated: 7/9/15

*****Nonformulary for outpatient benefit. PA required on medical benefit.*****

1. Does the member one of the following diagnoses?

- Exudative (Wet) Age-Related Macular Degeneration (AMD); or
- Diabetic Macular Edema; or
- Diabetic Retinopathy in DME; or
- Macular Edema following Retinal or Branch Retinal Vein Occlusion (RVO or BRVO)

If yes, continue to #2

If no, do not approve.

2. Has the member tried and failed Avastin?

If yes, approve for life.

If no, do not approve and recommend Avastin.

Generic Name: Albendazole

Brand Name: Albenza

Created: 7/19/16

1. Does the member have a diagnosis of pinworm?

If yes, continue to #2.

If no, continue to #3.

2. Has the member tried and failed Pin-X?

If yes, approve x 2 weeks

If no, deny.

3. Is the use for a supported indication and used with an appropriate dose and duration?

If yes, approve.

If no, deny.

Generic Name: Alemtuzumab

Brand Name: Lemtrada

Created: 12/28/11

Revised: 9/12/13, 3/2/15, 03/10/16

*****Nonformulary on outpatient benefit. PA required for medical benefit. *****

Initial Criteria:

1. Is Lemtrada being prescribed by a neurologist?
If yes, continue to #2. If no, do not approve.
2. Is the request for the treatment of relapsing, remitting multiple sclerosis (RRMS)?
If yes, continue to #3. If no, do not approve.
3. Has the member tried and failed ALL of the following?
 - a. Interferon (such as Rebif, Avonex, Extavia, Betaseron, Plegridy)
 - b. Copaxone
 - c. Tecfidera
 - d. Gilenya
 - e. TysabriIf yes, approve x 12 months (5 doses). If no, do not approve.

Renewal Criteria:

1. Is the request for a second year of Lemtrada?
If yes, continue to #2. If no, do not approve. Only labeled for 2 years
2. Did the member show documented response to Lemtrada?
If yes, approve x 12 months for 3 additional doses If no, do not approve.

Generic Name Alpha 1-Proteinase Inhibitor Human

Brand Name Prolastin, Aralast, Zemaira, Glassia

Reviewed: 12/2/11, 9/12/13

Initial Criteria:

1. Is the member a current smoker?

 If yes, continue to #2.

 If no, continue to #3.

2. Is the member enrolled in a smoking cessation program and abstinent for at least 6 months?

 If yes, continue to #3.

 If no, do not approve

3. Is the request from a pulmonologist?

 If yes, continue to #4.

 If no, do not approve.

4. Does the member have ZZ or Z/null AAT deficiency?

 If yes, continue to #5.

 If no, do not approve.

5. Does the member have an AAT serum level $\leq 11\mu\text{M}$ or 50mg/dL?

 If yes, continue to # 6.

 If no, do not approve.

6. Does the member have a diagnosis of moderate emphysema and/or an FEV₁ between 30-65%?

 If yes, continue to #7.

 If no, do not approve.

7. Is the member currently undergoing or has undergone?

 a. Pulmonary rehabilitation, **and**

 b. Weight loss and nutritional support, if indicated.

 If yes, continue to #8.

 If no, do not approve.

8. Has the provider outlined specific, measurable treatment goals such as?

 a. Slowing of FEV₁ decline, **and**

 b. Lack of disease progression.

 If yes, approve for 12 weeks.

 If no, do not approve.

Renewal Criteria:

1. Is the member meeting treatment goals?

 If yes, approve for 12 months

 If no, do not approve.

Generic Name: Apremilast

Brand Name: Otezla

Created: 7/22/14

Reviewed: 01/08/15

Revised: 01/12/17

Psoriatic arthritis:

Initial Criteria:

1. Is the request from a rheumatologist or dermatologist?
If yes, continue to #2. If no, do not approve.

2. Does the member have a diagnosis of psoriatic arthritis based on at least 3 out of 5 of the following?
 - Psoriasis (1 point for personal or family history, 2 points for current)
 - Psoriatic nail dystrophy
 - Negative rest result for RF
 - Dactylitis (current or history)
 - Radiological evidence of juxta-articular new bone formationIf yes, continue to #3. If no, do not approve.

3. Has the member failed all of the following:
 - NSAIDs,
 - At least two DMARDs such as methotrexate, sulfasalazine, or leflunomide.If yes, continue to #4. If no, do not approve.

4. Approve for 6 months.

Psoriatic arthritis:

Renewal Criteria:

1. Does the member have documented, clear treatment response from therapy such as improved reduction in swollen joint counts, improved psoriasis, or functional improvement?
If yes, approve for 12 months. If no, do not approve.

Plaque psoriasis:

Initial criteria:

1. Does the member have chronic, moderate to severe Plaque Psoriasis with functional impairment and one or more of the following:
 - a. At least 10% body surface area involved
 - b. Hand, foot or mucous membrane involvementIf yes, continue to #2. If no, do not approve.

2. Has the treatment been prescribed or is it currently being supervised by a dermatologist?
If yes, continue to #3. If no, do not approve.

3. Has the member tried and failed or have contraindications to **ALL** of the following:
 - High-potency topical corticosteroids (betamethasone dipropionate, clobetasol, fluocinonide)
 - At least one other topical agent: calcipotriene, tazarotene, anthralin
 - PUVA or UVB Phototherapy
 - Methotrexate
 - At least one other systemic agent: cyclosporine or acitretin.If yes, continue to #4. If no, do not approve

4. Approve for 6 months.

Renewal Criteria:

Plaque Psoriasis

1. Has the member experienced a 50% reduction in plaques and/or is there evidence of functional improvement?
If yes, approve for 12 months. If no, do not approve.

Generic Name Aprepitant

Brand Name Emend

Revised: 12/24/09, 1/4/11, 11/15/16

Reviewed: 9/13/12, 9/12/13

1. Is the member currently receiving treatment with a moderate to highly emetogenic chemotherapeutic agent?

 If yes, continue to #2.

 If no, do not approve.

1. Is the member receiving concurrent treatment with IV or oral Zofran (ondansetron) or Kytril (granisetron) or Aloxi (palonosetron) **and** dexamethasone [verify with PA and claims profile]?

 If yes, continue to #3.

 If no, do not approve.

2. Is the request for suspension packets?

 If yes, continue to #4

 If no, continue to #5

3. Is the member unable to use capsules?

 If yes, continue to #5

 If no, deny for criteria not met.

4. Approve up to 5 cycles.

Generic Name: Aztreonam

Brand Name: Cayston

Created: 9/15/10

Reviewed: 12/2/11, 7/12/12, 9/12/13

Revised: 10/2/12, 1/25/17

Initial Criteria:

1. Does the member have a diagnosis of cystic fibrosis?
If yes, continue to #2. If no, do not approve.
2. Is the member ≥ 7 years of age?
If yes, continue to #3. If no, do not approve.
3. Is the member's FEV1 between 25% and 75% predicted?
If yes, continue to #4. If no, do not approve.
4. Does the member have documentation of *Pseudomonas aeruginos* infection?
If yes, continue to #5. If no, do not approve.
5. Has the member failed or has documented resistance to tobramycin (TOBI)?
If yes, approve for 12 months. If no, do not approve.

Renewal Criteria:

1. Has the member demonstrated compliance with therapy and a clinical response such as increased FEV1 from baseline or improvement in respiratory symptoms?
If yes, approve for 12 months If no, do not approve.

Generic Name Belatacept

Brand Name Nulojix

Created: 11/29/11

Revised: 9/12/13

***** Nonformulary on outpatient benefit. PA required on medical benefit. *****

1. Is the request from a nephrologist or transplant specialist?
If yes, continue to #2. If no, do not approve.
2. Is the request for prophylaxis of organ transplant in a member who had a kidney transplant?
If yes, continue to #3. If no, do not approve.
3. Has the member failed (acute rejection, side effects, or inability to comply with oral therapy) or has contraindications to tacrolimus and cyclosporine?
If yes, continue to #4. If no, do not approve.
4. Is the member Epstein-Barr virus positive?
If yes, continue to #5. If no, do not approve.
5. Will Nulojix be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids?
If yes, continue to #6. If no, do not approve.
6. Approve for life.

Generic Name Belimumab

Brand Name Benlysta

Created: 9/19/11

Revised: 9/12/13

***** Nonformulary on outpatient benefit. PA required on medical benefit. *****

Initial Criteria:

1. Is Benlysta being prescribed by or in consultation with a rheumatologist?

If yes, continue to #2.

If no, do not approve.

2. Does the member have a diagnosis of active, autoantibody-positive systemic lupus erythematosus (SLE) and is currently receiving standard therapy (see number 3)?

If yes, continue to #3.

If no, do not approve.

3. Does the member have a Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA-SLEDAI) score of ≥ 6 ?

If yes, continue to #4.

If no, do not approve.

4. Does the member have severe active lupus nephritis or severe active central nervous system lupus?

If yes, do not approve.

If no, continue to #5.

5. Has the member failed all of the following (alone or in combination)?

- NSAIDs
- Corticosteroids
- Antimalarials (primarily hydroxychloroquine)
- Immunosuppressives (e.g. cyclophosphamide, cyclosporine, tacrolimus, leflunomide, azathioprine, mycophenolate, and methotrexate)

If yes, continue to #6.

If no, do not approve.

6. Is the member currently on another biologic and/or IV cyclophosphamide?

If yes, do not approve.

If no, continue to #7.

7. Has the prescriber outlined specific and measurable treatment goals to assess a 6 month trial?

If yes, approve for 6 months. Approve 10mg/kg every 2 weeks for the first 3 doses then 10mg/kg every 4 weeks. Total fill of 7.

If no, request treatment plan.

Renewal Criteria:

1. Is there medical record documentation of any of the following?

- SELENA-SLEDAI score point reduction of 4 or more.
- Provider has indicated that there is no worsening of disease from baseline after treatment with belimumab.
- British Isles Lupus Assessment Group (BILAG) Classic Index that measures organ specific changes in disease activity in the past 28 days that indicates no new BILAG A score and no more than one new BILAG B score compared with baseline.
- No worsening of disease activity requiring intensification of therapy with high-dose steroids or immunosuppressants.
- Experienced a dose reduction of steroid therapy.

If yes, approve for 6 months.

If no, do not approve

Approve 10mg/kg every 4 weeks

Total fills of 7

Generic Name: Bevacizumab

Brand Name: Avastin

Created: 12/28/11

Revised: 10/2/12, 1/18/13, 3/28/13, 9/12/13, 8/21/14, 11/5/14, 12/12/14

*****Nonformulary on outpatient benefit. PA required for medical benefit.*****

1. Is Avastin being prescribed by an oncologist or ophthalmologist?
If yes, continue to #2. If no, do not approve.
2. Is the member at least 18 years of age?
If yes, continue to #3. If no, do not approve.
3. Is the intended use for in the eye?
If yes, continue to #5. If no, continue to #4.
4. Is the diagnosis one of the following:
 - a. Metastatic colorectal cancer
 - i. First- or second-line therapy, in combination with IV 5-fluorouracil-based chemotherapy
 - ii. Second-line therapy, in combination with fluoropyrimidine/irinotecan- or fluoropyrimidine/oxaliplatin-based chemotherapy, in patients who have progressed on a first-line bevacizumab-containing regimen
 - iii. Not indicated for adjuvant treatment for stage II or III disease
 - b. Advanced nonsquamous, nonsmall cell lung cancer
 - i. Recurrent or metastatic, unresectable, locally advanced, first-line treatment in combination with paclitaxel and carboplatin
 - c. Metastatic HER-2 negative breast cancer who have not received chemotherapy for metastatic disease
 - d. Glioblastoma multiforme of brain, Recurrent, progressive disease following prior therapy
 - e. Metastatic renal cell cancer in combination with interferon alfa
 - f. Persistent, recurrent, or metastatic carcinoma of the cervix in combination with paclitaxel and cisplatin or paclitaxel and topotecan
 - g. Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel that is platinum-resistant and has received no more than two prior chemotherapy regimens

If yes, continue to #6. If no, review for NCCN supported uses
5. Is the request for a supported off-label use (such as age-related macular degeneration, diabetic macular edema, etc)?
If yes, continue to #7. If no, do not approve.
6. Approve for 12 months.

7. Approve for lifetime.

Generic Name Bosentan

Brand Name Tracleer

Revised: 4/28/10, 9/11/14

Reviewed: 9/13/12, 9/12/13

1. Is Tracleer being requested by a pulmonologist or cardiologist?
If yes, continue to #2. If no, do not approve
2. Is the member a current smoker?
If yes, continue to #3. If no, continue to #4.
3. Is the member enrolled in a smoking cessation program?
If yes, continue to #4. If no, do not approve.
4. Does the member have a diagnosis of pulmonary arterial hypertension WHO Group I diagnosed by right heart catheterization?
If yes, continue to #5. If no, do not approve. WHO Groups 2-5 not indicated.
5. Does the member meet all of the following criteria?
 - a. Mean PAP \geq 25 mm Hg at rest and
 - b. Pulmonary Capillary Wedge Pressure \leq 15 mm Hg at rest, and
 - c. NYHA functional class II to IV symptomsIf yes, continue to #6. If no, do not approve.
6. Has the member had a positive response to vasoreactivity testing such as?
 - a. \geq 25% reduction in mean PVR, or
 - b. Fall in mean PAP of at least 10 and \leq 40mm Hg, or
 - c. Increase or unchanged cardiac output.If yes, do not approve. If no, continue to #7.
Calcium channel blocker is indicated.
7. Has the member tried and failed or have contraindication to sildenafil?
If yes, approve x 16 weeks. If no, do not approve.

Renewal Criteria:

1. Does the member meet any of the following treatment goals?
 - a. A significant increase in the 6-minute walk test, or
 - b. Decrease in dyspnea fatigue rating and other symptoms, or

- c. Evidence of hemodynamic improvement such as a reduction in mPAP and PVR, or
- d. Improvement in NYHA functional class, or
- e. Lack of functional or hemodynamic deterioration

If yes, approve for 12 months.

If no, do not approve.

- Multiple sclerosis
 - Neuromyelitis optica
 - Other demyelinating diseases of the central nervous system
- If yes, continue to #7. If no, do not approve.

7. Is the member at least 18 years old?
If yes, continue to #9. If no, continue to #8.
8. Is the request for Dysport for the treatment of lower limb spasticity in a member at least 2 years old?
If yes, continue to #9. If no, do not approve.
9. Is abnormal muscle tone causing functional impairment or expected to result in joint contracture?
If yes, continue to #10. If no, do not approve.
10. Has the member tried and failed or have contraindications to conventional non-pharmacologic treatment including physical therapy, splinting, bracing, or biofeedback which has been ineffective or cannot be maximized secondary to significant contracture?
If yes, continue to #11. If no, do not approve.
11. Has the member tried and failed two oral pharmacologic agents, such as baclofen, dantrolene, tizanidine, and benzodiazepines?
If yes, continue to #12. If no, do not approve.
12. Approve for 12 months.

Renewal Criteria:

1. Has the member met treatment goals, including but not limited to the following?
- Decrease in severity of abnormal movements or contractures such as head positioning, improved range of motion, or decreased spasticity
 - Decrease in pain
 - Decrease in disability, such as enhanced motor ability and functional skills, improved execution of tasks, or improvement in activities of daily living.
- If yes, approve for 12 months. If no, do not approve.

Chronic Migraine:

Initial Criteria:

1. Is the request made by or supervised by a neurologist or pain specialist?
If yes, continue to #2. If no, do not approve.
2. Is the member at least 18 years old?
If yes, continue to #3. If no, do not approve.

3. Does the member have a diagnosis of chronic migraine, defined as greater than or equal to 15 days per month with headache lasting 4 hours per day or longer?
If yes, continue to #4. If no, do not approve.
4. Are headaches the result of medication overuse/rebound defined as using narcotics, triptans, butalbital, or ergotamine greater than 12 days a month?
If yes, do not approve. If no, continue to #5.
5. Has the member had adequate trial of or contraindications to at least one medication from each of the following drug classes?
 - Anticonvulsants such as divalproex, topiramate, or gabapentin
 - Beta Blockers such as atenolol, nadolol, or propranolol
 - Tricyclic Antidepressants such as amitriptyline, nortriptyline, or desipramine
 If yes, approve for 6 months. If no, do not approve.

Renewal Criteria:

1. Has the member showed decreased number of migraine days or less migraine episodes or decreased narcotics usage and/or ED visits?
If yes, approve 12 months. If no, do not approve.

Urinary Incontinence/Overactive Bladder

Initial Criteria:

1. Is the request made by or supervised by a neurologist or urologist?
If yes, continue to #2 If no, do not approve.
2. Is the member at least 18 years old?
If yes, continue to #3. If no, do not approve.
3. Does the member have a diagnosis of urinary incontinence associated with a neurologic condition (spinal cord injury, cauda equina, or multiple sclerosis)?
If yes, continue to #6. If no, continue to #4.
4. Does the member have a diagnosis of overactive bladder with symptoms of urge incontinence, urgency and frequency?
If yes, continue to #5. If no, do not approve.
5. Has the member tried and failed conservative therapies including bladder training, pelvic floor muscle exercises, and fluid management?
If yes, continue to #6. If no, do not approve.
6. Has the member failed at least 2 anticholinergic medications (such as oxybutynin and tolterodine)?
If yes, approve for 6 months. If no, do not approve.

Renewal Criteria:

1. Has there been documentation of benefit, such as decreased incontinence episodes or frequency?
If yes, approve for 12 months
If no, do not approve.

Strabismus

Initial criteria:

1. Is the request made by or supervised by an ophthalmologist or neurologist?
If yes, continue to #2.
If no, do not approve.
2. Is the member at least 12 years old?
If yes, continue to #3.
If no, do not approve.
3. Does the member have functional impairment related to strabismus due to other neurologic disorders?
If yes, approve one injection for 3 months
If no, do not approve.

Achalasia

Initial criteria:

1. Is the request made by or supervised by a gastroenterologist?
If yes, continue to #2.
If no, do not approve.
2. Does the member have a diagnosis of achalasia?
If yes, continue to #3.
If no, do not approve.
3. Has the member remained symptomatic after a prior pneumatic dilation or surgical myotomy?
If yes, continue to #4.
If no, do not approve.
4. Is the member a high surgical risk for pneumatic dilation or surgical myotomy?
If yes, continue to #6.
If no, continue to #5.
5. Has the member presented with atypical achalasia symptoms and botulinum toxin is needed to help guide therapy or confirm diagnosis?
If yes, continue to #6
If no, do not approve.
6. Approve for 3 months.

Renewal Criteria:

1. Has there been a response to botulinum toxin, such as reduction in symptoms of dysphagia or reflux?
If yes, approve for 12 months.
If no, do not approve.

Generic Name Buprenorphine Implant

Brand Name Probuphine (implant)

Created: 10/31/16.

***** Nonformulary on outpatient benefit. PA required for medical benefit *****

1. Is the member currently on or have they been maintained for at least 6 months on no more than 8mg/day of buprenorphine or buprenorphine/naloxone SL tablets?

If yes, go to #2

If no, deny*

2. Is the member clinically stable? Consider the following factors in determining clinical stability:

- Provider overall assessment
- Abstinent for at least 90 days with no need for supplemental dosing
- No significant withdrawal symptoms or cravings
- No reported hospitalizations (addictions or mental health issues), ER visits or crisis interventions in the last 90 days
- Consistent participation in recommended behavioral health therapy/ peer support program and compliance with provider visits

If yes, go to #3

If no, deny*

3. Is there documented medical reasoning it would be clinically inappropriate to continue with maintenance therapy on SL buprenorphine or generic Suboxone?

If yes, approve x 6 months

If no, deny

Generic Name Calcipotriene Cream
 Calcipotriene Solution

Brand Name Dovenox Cream
 Dovenox Solution

Created: 09/10/15

1. Does the member have a diagnosis of moderate to severe psoriasis that is funded on the OHP?

 If yes, continue to #2.

 If no, do not approve.

2. Has the member failed at least one ultra-high potency topical steroid?

 If yes, approve for lifetime.

 If no, do not approve.

Generic Name Cabozantinib

Brand Name Cabometyx

Created: 5/5/16

1. Does the member have a diagnosis of advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy

If yes, continue to #2.

If no, use general OHP
Chemotherapy PA criteria

2. Is the request from an oncologist?

If yes, continue to #3.

If no, do not approve

3. Is there a medical reason stated that the alternative Inlyta cannot be used instead (including review of NCCN guidelines to ensure still equal recommendation for Inlyta and Cabometyx)?

If yes, do not approve

If yes, approve x 12 months.

Renewal Criteria:

1. Has there been evidence of tumor response?

If yes, approve x 12 months.

If no, do not approve

Generic Name Candesartan, Candesartan/HCTZ
Valsartan, Valsartan/HCTZ

Brand Name Atacand, Atacand-HCT
Diovan, Diovan-HCT

Created: 03/31/16

1. Is the request for the treatment of reduced ejection fraction (systolic) heart failure?
If yes, continue to #2. If no, continue to #3.
2. Is documentation of intolerance or failure of an ACEI included with the request?
If yes, approve for lifetime If no, deny
3. Is the request for the treatment of hypertension?
If yes, continue to #4 If no, deny
4. Has the patient tried maximum tolerated doses of losartan **AND** irbesartan **AND** at least one medication from three of the following classes:
 - a. Calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil)
 - b. Beta blockers (metoprolol, carvedilol, atenolol)
 - c. Alpha blockers (prazosin, terazosin, doxazosin)
 - d. Thiazides (chlorthalidone, HCTZ)
 - e. Other (clonidine, spironolactone)

If yes, approve for lifetime If no, deny and offer untried agents

Generic Name: Capsaicin

Brand Name: Qutenza

Created: 7/15/10

Reviewed: 12/2/11, 7/12/12, 9/12/13

***** Nonformulary on outpatient benefit. PA required for medical benefit *****

1. Does the member have a diagnosis of postherpetic neuralgia?

If yes, continue to #2.

If no, do not approve.

2. Has the member failed ALL of the following?

a. Capsaicin cream

b. Tricyclic antidepressant (amitriptyline, nortriptyline, desipramine)

c. Gabapentin

d. Lyrica

If yes, continue to #3.

If no, do not approve.

3. Approve up to 4 patches x 3 months. Must be administered by a healthcare professional.

Generic Name C1 inhibitor (human)

Brand Name Cinryze

Created: 7/16/09

Revised: 01/25/12

Reviewed: 7/12/12, 9/12/13

***** Non-formulary on outpatient benefit. PA required on medical benefit *****

Initial criteria:

1. Does the member have a diagnosis of hereditary angioedema (HAE) confirmed by genetic testing or normal C1q lab levels with levels below the lab's normal reference range for both C4 and C1INH?
If yes, continue to #2. If no, do not approve.
2. Does the member have a history of at least two attacks per month which are considered severe with swelling of the face, throat or gastrointestinal tract that significantly interrupts usual daily activity despite short-term symptomatic treatment?
If yes, continue to #3. If no, do not approve.
3. Has the member been evaluated for triggers of HAE attacks and is maximally managed for avoidance of those triggers (such as stress, hormonal changes, dental surgery, trauma, medications including ACE inhibitors and estrogen)?
If yes, continue to #4. If no, do not approve.
4. Has the member failed treatment with androgen therapy (i.e. danazol)?
If yes, continue to #5. If no, do not approve and recommend a trial of danazol.
5. Is treatment with acute, abortive therapy an option for this member (Firazyr, Berinet)?
If yes, do not approve If no, continue to #6.
6. Review case with medical director for consideration of approval.
Long-term prevention: 1000 units IV q 3-4 days.
Short-term prevention: 1000 units per procedure.

Renewal criteria:

1. Has there been at least a 50% reduction in the number of angioedema attacks, significant improvement in the severity and duration of attacks, and clinical documentation of functional improvement?
If yes, approve previous qty as above x 1 month. If no, do not approve.

Generic Name Ceftazidime/Avibactam
Brand Name Avycaz

Created: 07/23/15

Initial Criteria:

1. Is there documentation to support the use of this new antibiotic such as extensive resistance to common antibiotic agents including ceftazidime alone? Such documentation may include or require Infectious Disease consult notes.

If yes, continue to #2.

If no, deny.

2. Approve for duration clinically necessary.

Generic Name Celecoxib

Brand Name Celebrex

Revised: 8/6/09, 9/19/11, 4/29/16

Reviewed: 9/13/12, 9/12/13

1. Is the member at high-risk for GI complications from long-term use of NSAIDs as defined as one of the following?
 - a. History of GI bleed
 - b. Active peptic ulcer documented through endoscopy
 - c. High risk of GI bleed (at least 3 of the following):
 - i. History of peptic ulcer disease
 - ii. Age >65
 - iii. Long-term use of oral steroids
 - iv. Long-term use of anticoagulants or antiplatelets (eg warfarin or clopidogrel)
 - v. Male gender
 - vi. History of Dyspepsia

If yes, continue to #2.

If no, do not approve

2. Is the member currently on aspirin? (Concurrent use of aspirin with celecoxib eliminates any gastroprotective benefit of celecoxib.)

If yes, do not approve.

If no, continue to #3.

3. Has the member failed a trial meloxicam and etodolac (requires PA and failure of meloxicam)?

If yes continue to #4

If no, do not approve

4. Approve for life.

Generic Name Chemotherapy [#chemotherapy](#)

• Abraxane	Paclitaxel Protein	• Kisqali	Ribociclib
• Adcetris	Brentuximab	• Kyprolis	Carfilzomib
• Afinitor	Everolimus	• Lartruvo	Olaratumab
• Alcensa	Alectinib	• Lenvima	Lenvatinib
• Alimta	Pemetrexed	• Lonsurf	Trifluridine-Tipiracil
• Alkeran	Melphalan	• Lynparza	Olaparib
• Arranon	Nelarabine	• Mekinist	Trametinib
• Arzerra	Ofatumumab	• Nexavar	Sorafenib
• Atezolizumab	Tecentriq	• Ninlaro	Ixazomib
• Avastin	Bevacizumab	• Odomzo	Sonidegib
• Bavencio	avelumab	• Oncaspar	Pegaspargase
• Beleodaq	Belinostat	• Onivyde	Irinotecan Lipo
• Bendeka	Bendamustine	• Opdivo	Nivolumab
• Blinicyto	Blinatumomab	• Perjeta	Pertuzumab
• Bosulif	Bosutinib	• Pomalyst	Pomalidomide
• Brigatinib	Alunbrig	• Portrazza	Necitumumab
• Caprelsa	Vandetanib	• Revlimid	Lenalidomide
• Cometriq	Cabozantinib	• Rubraca	Rucaparib
• Cotellic	Cobimetinib	• Sprycel	Dasatinib
• Cyramza	Ramucirumab	• Stivarga	Regorafenib
• Dacogen	Decitabine	• Sutent	Sunitinib
• Darzalex	Daratumumab	• Sylatron	Peginterferon
• Docefrez	Docetaxel	• Sylvant	Siltuximab
• Doxil	Doxorubicin Lipo	• Synribo	Omacetaxine
• Durvalumab	Imfinzi	• Tafinlar	Dabrafenib
• Eloxatin	Oxaliplatin	• Tagrisso	Osimertinib
• Empliciti	Elotuzumab	• Tarceva	Erlotinib
• Erbitux	Cetuximab	• Tassigna	Nilotinib
• Erivedge	Vismodegib	• Taxotere	Docetaxel
• Erwinaze	Asparaginase	• Temodar	Temozolamide
• Evomela	Melphalan	• Torisel	Temsirolimus
• Farydak	Panobinostat	• Treanda	Bendamustine
• Faslodex	Fulvestrant	• Trelstar	Triptorelin
• Firmagon	Degarelix	• Tykerb	Lapatinib
• Folutyn	Pralatrexate	• Unituxin	Dinutuximab
• Fusilev	Levoleucovorin	• Vantas	Histrelin
• Gazyva	Obinutuzumab	• Vectibix	Panitumumab
• Gilotrif	Afatinib	• Velcade	Bortezomib
• Gleevec	Imatinib	• Venclexta	Venetoclax
• Halaven	Eribulin	• Votrient	Pazopanib
• Herceptin	Trastuzumab	• Xalkori	Crizotinib

- | | | | |
|-------------|-----------------|------------|-----------------|
| • Ibrance | Palbociclib | • Xtandi | Enzalutamide |
| • Iclusig | Ponatinib | • Yervoy | Ipilimumab |
| • Imbruvica | Ibrutinib | • Yondelis | Trabectedin |
| • Imlygic | Talimogene | • Zaltrap | Ziv-Aflibercept |
| • Inlyta | Axitinib | • Zejula | Niraparib |
| • Iressa | Gefitinib | • Zelboraf | Vemurafenib |
| • Istodax | Romidepsin | • Zolinza | Vorinostat |
| • Ixempra | Ixabepilone | • Zydelig | Idelalisib |
| • Jevtana | Cabazitaxel | • Zykadia | Ceritinib |
| • Kadcyca | Ado-Trastuzumab | • Zytiga | Abiraterone |
| • Keytruda | Pembrolizumab | | |

Created: 03/10/2016

Updated: 5/17/16, 7/18/16, 11/15/16, 1/25/17, 5/11/17

*****Office administered infusions/injections are nonformulary on outpatient benefit. PA required for medical benefit. *****

Initial Criteria:

1. Is the treatment being prescribed by a hematologist or oncologist, as appropriate, for the type of cancer?

If yes, continue to #2.

If no, do not approve.

2. Is the treatment supported for the diagnosis in the NCCN guidelines?

If yes, continue to #4.

If no, continue to #3.

3. Is the treatment being used according to the FDA indication?

If yes, continue to #4

If no, do not approve.

4. Does the request meet criteria for treatment coverage specified in Guideline Note 12 of the Prioritized List of Health Services, considering treatment of cancer with little or no benefit?

If yes, continue to #5

If no, do not approve.

5. Approve x 12 months.

Renewal Criteria:

1. Has there been evidence of tumor response?

If yes, approve x 12 months.

If no, do not approve.

Generic Name: Clonazepam

Brand Name: Klonopin

Created: 6/23/16

1. Does the member have a seizure diagnosis?

Yes, approve for life.

No, continue to #2

2. Does the member have a terminal illness or in palliative care?

Yes, approved for life.

No, continue to #3

3. Is the request for short term use (4 weeks or less) AND member is not on opiates or other sedative hypnotics?

Yes, approve for 1 month.
every 120 days

No, continue to #4.

4. For chronic use, are all of the following met?

a. Used for a supported indication

b. Supported and clear clinical rationale to support-long term clonazepam use

c. No concurrent use of opioids or sedative/hypnotics

Yes, approve for 12 months.

No, deny for not medically appropriate.

Generic Name Daclizumab

Brand Name Zinbryta

Created: 11/15/16

1. Is the member ≥ 18 years old and has a diagnosis of relapsing-remitting multiple sclerosis?

 If yes, continue to #2

 If no, deny.

2. Is treatment requested by or in consultation with a neurologist?

 If yes, continue to #3

 If no, deny

3. Has the member failed* or have contraindications to treatment with one of the following?

 a. Interferon β (Avonex, Rebif, Plegridy, Extavia or Betaseron) **OR**

 b. Glatiramir acetate (Copaxone, Glatopa) **OR**

 c. Teriflunomide (Aubagio) **OR**

 d. Natalizumab (Tysabri)

 If yes, continue to #4

 If no, deny

4. Has the member failed* or have contraindications to treatment with Dimethyl fumarate (Tecfidera)?

 If yes, continue to #5

 If no, deny

5. Approve daclizumba (Zinbryta) 150 mg injection once a month for 12 months.

*Note: For treatment failure, all of the following must be documented in the medical record:

a. Member compliance with previous regimens

b. Continuation of clinical relapses or CNS lesion progression on MRI or worsening disability

Generic Name: Defibrotide Sodium

Brand Name: Defitelio

Date Created: 07/19/16

***** Nonformulary on outpatient benefit. PA required for medical benefit. *****

1. Is the request for PROPHYLAXIS of hepatic veno-occlusive disease from hematopoietic stem-cell transplantation (HSCT)?

If yes, deny for investigational.

If no, continue to #2.

2. Is the request for acute treatment of hepatic veno-occlusive disease from hematopoietic stem-cell transplantation (HSCT)?

If yes, approve.

If no, deny.

Note: CareOregon expects acute treatment would begin during an acute hospitalization where PA is not required for drugs. PA is only required for pre-planned hospitalizations or outpatient infusion services.

Generic Name Denosumab

Brand Name Prolia

Created 12/7/10

Revised: 11/29/11, 7/13/12, 11/8/12

Reviewed: 9/12/13

***** Nonformulary on outpatient benefit. PA required for medical benefit. *****

1. Is the member a post-menopausal female with osteoporosis and high risk of fracture with ONE of the following:
 - a. Radiographic evidence of an osteoporotic fracture while compliant on a oral bisphosphonate or intranasal calcitonin-salmon for ≥ 12 months
 - b. High risk of fracture AND a) documented adverse event with an oral bisphosphonate or intranasal calcitonin-salmon despite proper administration or b) contraindication to oral bisphosphonate or intranasal calcitonin-salmon.

If no, do not approve. Recommend alendronate or calcitonin-salmon.
Continue to #2 for other diagnoses.

If yes, approve for 12 months, fill count of 2.

2. Does the member have a diagnosis of ONE of the following?
 - a. Nonmetastatic prostate cancer and receiving androgen deprivation therapy (ADT)
 - b. Breast cancer receiving adjuvant aromatase inhibitor (AI) therapy
 - c. Male with osteoporosis

If yes, continue to #3.

If no, do not approve.

3. Is the member at high risk for fracture?

If yes, continue to #4.

If no, do not approve.

4. Has the member failed a trial of a bisphosphonate (radiographic evidence of fracture while compliant on an oral bisphosphonate for ≥ 12 months or documented adverse event or contraindication to an oral bisphosphonate)?

If yes, approve x 12 months,
fill count of 2.

If no, do not approve.

Generic Name Denosumab

Brand Name Xgeva

Created: 3/10/11

Reviewed: 7/12/12, 9/12/13

Revised: 9/16/13, 2/17/15

***** Nonformulary on outpatient benefit. PA required for medical benefit. *****

1. Does the member have a diagnosis of bone metastases from solid tumors?
If yes, go to #2. If no, continue to #3.
2. Has an zoledronic acid been tried first or is there a contraindication to zoledronic acid that is not a contraindication to denosumab?
If yes, approve x 12 months. If no, do not approve.
3. Does the member have a diagnosis of giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity?
If yes, approve x 12 months. If no, continue to #4
4. Does the member have a diagnosis of hypercalcemia of malignancy (HCM)?
If yes, continue to #5. If no, do not approve.
5. Has a bisphosphonate such as zoledronic acid (Zometa) or pamidronate (Aredia) been tried first or is there a contraindication to either?
If yes, approve x 12 months. If no, do not approve.

Generic Name Dimethyl fumarate

Brand Name Tecfidera

Created: 5/9/13

Reviewed: 9/12/13

1. Is the member age 18 or older?
If yes, continue to #2. If no, do not approve.

2. Does the member have a diagnosis of relapsing, remitting multiple sclerosis?
If yes, continue to #3. If no, do not approve.

3. Is the request for monotherapy and is not intended to be used in combination with other MS agents?
If yes, approve x life. If no, do not approve.

Generic Name Dronabinol

Brand Name Marinol

Reviewed: 12/2/11

Revised: 9/26/12, 9/12/13, 01/08/15

1. Does the member have nausea and vomiting associated with HIV/AIDS or cancer **and** is undergoing chemotherapy or radiation therapy?

If yes, continue to #3.

If no, continue to #2.

2. Does the member have a diagnosis of HIV/AIDS anorexia associated with weight loss or cachexia?

If yes, continue to #4.

If no, forward to the PA Pharmacist.

3. Has the member tried and failed or does the member have a contraindication to the following?

i) At least **TWO** of the following formulary alternatives:

- (1) dimenhydrinate, or
- (2) meclizine, or
- (3) metoclopramide, or
- (4) promethazine, or
- (5) prochlorperazine

AND

ii) Oral Zofran (ondansetron):

If yes, continue to #5.

If no, do not approve.

4. Has the member tried and failed or have a contraindication to Megace (megestrol)?

If yes, continue to #5.

If no, do not approve.

5. Approve for 12 months.

Generic Name Dronedarone

Brand Name Multaq

Created: 01/14/16

1. Is Multaq being requested by or supervised by a cardiologist?

 If yes, continue to #2.

 If no, do not approve.

2. Does the member meet any of the following exclusionary criteria?

- symptomatic heart failure with recent decompensation requiring hospitalization
- NYHA Class IV heart failure
- Permanent atrial fibrillation that will not or cannot be cardioverted into normal sinus rhythm.

 If yes, do not approve.

 If no, continue to #3.

3. Has the member tried and failed or have a contraindication to amiodarone?

 If yes, continue to #4.

 If no, do not approve.

4. Approve for lifetime.

Generic Name Eculizumab

Brand Name Soliris

Revised: 6/2/08, 11/29/11

Reviewed: 7/12/12, 9/12/13

***** Nonformulary on outpatient benefit. PA required for medical benefit. *****

1. Does the member have a diagnosis of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy or paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis?

If yes, continue to #2.

If no, do not approve.

2. Is the member being followed by a hematologist or a specialist in this area?

If yes, forward to RPh

If no, do not approve.

.

4. If the patient is on active Hep C treatment, have they dose reduced their peg-interferon according to FDA labeling of that product?
If yes, continue to #6. If no, do not approve.
5. If the patient has not started Hep C treatment, do they meet HepC treatment PA criteria?
If yes, continue to #6. If no, do not approve.
6. Is Promacta being used to treat thrombocytopenia to allow the initiation and maintenance of interferon-based therapy?
If yes, continue to #7. If no, do not approve.
7. Approve Promacta for 4 weeks.

Initial Criteria:

Aplastic anemia:

1. Does the member have a diagnosis of aplastic anemia?
If yes, continue to #2 If no, do not approve.
2. Is Promacta being prescribed by a hematologist?
If yes, continue to #3 If no, do not approve.
3. Is there medical record documentation of platelet count of less than or equal to 30,000 per mm³?
If yes, continue to #4 If no, do not approve.
4. Had the member failed immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine?
If yes, continue to #5 If no, do not approve.
5. Approve for 16 weeks.

Renewal criteria:

ITP:

1. Is there medical record documentation of ALL of the following?
 - a. Liver enzymes and bilirubin lab tests every 2 weeks for the first 3 months and monthly thereafter according to the manufacturer's recommendation
 - b. Maintenance of platelet counts between 30,000 per mm³ and 150,000 per mm³ or an increase in platelet counts from baseline with resolution of bleeding episodes
If yes, approve x 24 weeks. If no, do not approve.

Renewal Criteria:

Hepatitis C:

1. Have platelets increased to above 50,000 per mm³ or increased from baseline that allowed initiation/maintenance of interferon based treatment?

If yes, approve x 12 months.

If no, do not approve.

Renewal criteria:

Aplastic anemia:

1. Is there medical record documentation of ALL of the following?
 - a. Liver enzymes and bilirubin lab tests every 2 weeks for the first 3 months and monthly thereafter according to the manufacturer's recommendation
 - b. A hematologic response has occurred after 16 weeks of therapy?

If yes, approve x 6 months.

If no, do not approve.

- i. Non-MI related coronary revascularization
- ii. Residual CAD with at least 40% in 2 large vessels
- iii. HDL <40 for men, HDL < 50 for women
- iv. hsCRP> 2.0 mg/L
- v. LDL>=130
- vi. Metabolic syndrome

If yes, continue to #7

If no, continue to #6

6. Does the patient have an LDL-C greater than or equal to 100 mg while on maximum therapy (not baseline LDL) including ALL of the following?
- a. Rosuvastatin 40 mg (other high potency statins/doses not accepted unless dose increases not tolerated)
 - b. Ezetimibe
 - c. BAS

If yes, continue to #9.

If no, do not approve.

For stated statin contraindication, continue to #8

7. Does the patient have an LDL-C greater than or equal to 70 mg/dL while on maximum therapy (not baseline LDL) with ALL of the following?
- a. Rosuvastatin 40 mg (other high potency statins/doses not accepted unless dose increases not tolerated)
 - b. Zetia

If yes, continue to #9.

If no, do not approve.

For stated statin contraindication, continue to #8

8. Is the patient unable to tolerate high-intensity statin therapy documented by one of the following?
- c. Rhabdomyolysis
 - d. If on a low- to moderate-intensity statin: unable to push dose to high intensity due to persistent myalgia or myositis
 - e. If not on statin therapy: persistent myalgia or myositis despite a trial of a statin rechallenge with pravastatin or rosuvastatin.
 - d. If member has any modifiable factors which have been appropriately modified to address statin intolerance?
 - e. Is medically contraindicated to be on a statin regimen due to non-modifiable factors?

If yes, continue to #9.

If no, do not approve.

9. Will Repatha be used as adjunct to the following: a) statin and Zetia/BAS if not contraindicated, b) low-fat diet and c) exercise?

If yes, approve for 6 months.

If no, do not approve.

10. Is HoFH diagnosis confirmed with a genetic test?

If yes, approve x life.

If no, do not approve

First Renewal Criteria (after original approval)

1. Is the patient still continuing maximum adjunctive treatment (i.e. statin, Zetia/BAS, low fat diet, exercise)

If yes, continue to #2.

If no, do not approve.

2. Has the patient been adherent with Repatha?

If yes, continue to #3.

If no, do not approve.

3. Has there been a significant* LDL reduction while on Repatha? *Significant lowering of LDL-C is defined as a \geq 30% decrease in LDL-C.

If yes, approve x 12 months.

If no, do not approve.

Subsequent Renewals (after first renewal showed LDL lowering)

1. Has the patient been adherent?

If yes, approve x 12 months.

If no, do not approve.

7. Is the member currently anemic by the following definition?:

a. Men: Hemoglobin < 13 g/dL

b. Women: Hemoglobin < 12 g/dL

If yes, continue to #8.

If no, do not approve.

8. Approve for 3 months.

Renewal Criteria:

1. Is the member currently on epoetin (Procrit, Epogen) or darbepoetin (Aranesp) therapy and has maintained adequate iron stores (transferrin saturation > 20%)?

If yes, continue to #2.

If no, do not approve.

2. Has the member continued to see a response to treatment demonstrated by an increase from baseline Hb/Hct or maintenance at target Hb/Hct?

If yes, continue to #3.

If no, do not approve.

3. For chronic kidney disease and HIV/AIDS: Approve for 12 months.

For anemia of cancer/chemotherapy: Approve for 6 months.

- b. Decrease in dyspnea fatigue rating and other symptoms, or
- c. Evidence of hemodynamic improvement such as a reduction in mPAP and PVR, or
- d. Improvement in NYHA functional class, or
- e. Lack of functional or hemodynamic deterioration.

If yes, approve for 12 months.

If no, do not approve.

Generic Name Estradiol Valerate
 Estradiol Cypionate

Brand Name Depo-Estradiol
 Delestrogen

Created: 01/13/11

Updated: 7/13/17

1. Is the member under the age of 65?
 If yes, approve until age 65.

If not, see PA criteria for meds
high risk in the elderly.

Generic Name Etodolac

Brand Name Lodine

Created: 5/12/15

The following is Step Therapy coded criteria:

1. Has the member tried and failed meloxicam?
 If yes, approve for life

If no, do not approve.

First Renewal Criteria:

1. Has the member been adherent, had at least a 10% reduction in HbA1c, or HbA1c < 7.5% or FBS ≤ 120g/dl?

If yes, approve for 12 months.

If no, evaluate below.

Subsequent Renewal Criteria (applies only after a full response to GLP1 identified via 10% reduction):

1. Has at least one A1c been obtained in the previous 6 months?
 - i. A1c <9%. Approve x 12 months
 - ii. A1c ≥9%. Approve and recommend addition of basal or meal time insulin as appropriate.

Generic Name Famciclovir

Brand Name Famvir

Revised: 12/24/09, 9/19/11, 6/1/14, 6/20/16

Reviewed: 7/12/12, 9/12/13

1. Does the member have a diagnosis of acute herpes zoster or acute herpes simplex?
If yes, continue to #2. If no, continue to #4.
2. Is the member Immune compromised (HIV, cancer, transplant, etc.)?
If yes, continue to #6. If no, continue to #3.
3. Does the member have **ONE** of the following complications?
 - a. Herpetic gingivostomatitis, or
 - b. Herpes keratitis (ophthalmologic complications), or
 - c. Herpes encephalopathy (neurologic complications), or
 - d. Member is less than 2 years of age.If yes, continue to #7. If no, do not approve.
4. Does the member have a diagnosis of acute genital herpes?
If yes, continue to #7. If no, continue to #5.
5. Is the request for herpes simplex prophylaxis and the member meets one of the following criteria:
 - a. Member is pregnant and in the last trimester of pregnancy
 - b. Member is immunocompromised (HIV, cancer, transplant)If yes, continue to #7. If no, do not approve.
6. Does the member have HIV and is severely immunocompromised (CD4<200) and/or has disseminated zoster, multi-dermal zoster, or an outbreak on face or genitals?
If yes, continue to #8. If no, continue to #7.
7. Has the member tried and failed or experienced intolerable side effects to acyclovir and valacyclovir?
If yes, continue to #8. If no, do not approve .
8. Approve for duration:
 - For immunocompromised members: Approve for life.
 - For Pregnant members: May approve up to 3 months for members in the last trimester.
 - For all other members: Approve for up to one month .

Generic Name Ferric Carboxymaltose

Brand Name Injectafer

Created: 11/15/13

Revised: 01/14/16

*****Nonformulary on outpatient benefit. PA required for medical benefit. *****

1. Does the member have a diagnosis of iron deficiency anemia and is intolerant to oral iron or has not responded to oral iron?
 If yes, continue to #2 If no, do not approve.

2. Has rationale been provided for use of Injectafer over the preferred IV iron agents (Venofer, Ferrlecit)?
 If yes, approve x 12 months. If no, do not approve.

Generic Name Filgrastim (G-CSF)
 Pegfilgrastim
 Sargramostim (GM-CSF)
 Tbo-filgrastim

Brand Name Neulasta
 Leukine
 Zarxio

Revised: 11/20/08, 4/2/14, 11/23/15, 5/11/17

Reviewed: 12/2/11, 9/12/13, 8/1/15

1. Does the member have one of the following diagnoses/procedures for approval of the medication?
 - a. Receiving myelosuppressive chemotherapy for non-myeloid malignancies.
 - b. Bone marrow transplant (allogenic or autologous).
 - c. Autologous peripheral blood progenitor cells (PBPC) transplant.
 - d. Severe chronic neutropenia.
 - e. AIDS.
 - f. Myelodysplastic syndromes.

If yes, continue to #2.

If no, continue to #3.

2. Approve as follows:

- Zarxio- 3 months.
- Neulasta- 3 months with a Quantity limit of #1 syringe/month.
- Leukine- 3 months.

3. Does the member have a diagnosis of neutropenia associated with Hepatitis C treatment?

If yes, review for medical necessity.

If no, do not approve.

GROWTH HORMONE

Generic Name	Somatrem Somatotropin	
Brand Name	Genotropin – Subcutaneous Humatrope – Subcutaneous Norditropin - Subcutaneous Nutropin - Subcutaneous Nutropin AQ – Subcutaneous Nutropin Depot – Intramuscular	Omnitrope - Subcutaneous Saizen - Subcutaneous Seristim LQ - Subcutaneous Tev-Tropin - Subcutaneous Zorbtive - Subcutaneous

Revised: 8/27/10, 9/29/10, 11/2/10, 2/15/12, 9/26/12, 7/8/13, 1/25/17

Reviewed: 9/12/13

- **All preparations of Serostim are not covered**
- **GH is not covered for members who are 18 years or older. The clinical evidence show minimal benefit to enable member to attain or retain the capability for independence or self-care. OAR 410-141-0500(2)(a) and guideline note 74 in the Prioritized List of Health Services.**

Initial Criteria:

The following are required for all covered indications:

Note: All other indications that are not included in this policy are either considered investigational/experimental or not funded by OHP.

1. Is the member < 18 years old?
If yes, continue to #2
If no, do not approve..
2. Is this an initial PA request? (Verify both rx and medical claims history)
If yes, continue to #3
If no, continue to renewal criteria.
3. Is the prescriber a pediatric endocrinologist or pediatric nephrologist?
If yes, continue to #4
If no, do not approve.
4. Does the member have evidence of short stature or growth failure by one of the following:
 - Height standard deviation score (SDS) of more than 3 SD below the mean for chronological age or sex; **OR**
 - Height for age/sex is below the 3rd percentile (or greater than 2 SD below the mean **and** untreated growth velocity (GV) is below the 25th percentile* (must have at least one year of growth data); **OR**
 - Severe growth rate deceleration (GV measured over one year of more than 2 SD below the mean for age and sex)

If yes, continue to #5

If no, do not approve..

5. Does the member have one of the following diagnoses?

- a. Growth hormone deficiency
- b. Prader-Willi syndrome
- c. Turner's syndrome
- d. Chronic renal failure/insufficiency; pre-transplant
- e. Idiopathic short stature without GH deficiency

If yes for a-d, continue to the specific criteria for the diagnosis. If no, do not approve.

If yes for e, do not approve.

Dx is not on the Prioritized List and is not covered per guideline note 74.

Growth hormone deficiency (GHD)

1. Does the member have documented biochemical GHD by **ONE** of the following tests:
 - a. Two growth hormone (GH) stimulation tests < 10 ng/mL (microgram/L)
 - b. One GH stimulation test < 15 ng/mL and IGF – 1 below normal for bone age and sex

Note: GH stimulation test or IGF-1 are not needed for GHD if multiple pituitary hormone deficiencies exist (at least one other deficient hormone including Luteinizing hormone (LH), Follicle Stimulation Hormone (FSH), Thyroid stimulating hormone (TSH), and Adrenocorticotropic Hormone (ACTH).)

Note: GH stimulation test or IGF – 1 levels are not needed for congenital GHD (low GH level detected during acute episode of hypoglycemia)

If yes, continue to #2

If no, do not approve

2. For members over 12 years of age, is there evidence of non-closure of epiphyses confirmed by X-ray?

If yes, continue to #3

If no, do not approve

3. Approve for 12 months.

Prader-Willi Syndrome:

1. Does the member have a confirmed diagnosis of Prader-Willi syndrome (confirmed with genetic testing, decreased muscle tone by exam)?

If yes, continue to #2

If no, do not approve

2. For members over 12 years of age, is there evidence of non-closure of epiphyses confirmed by X-ray?

If yes, continue to #3

If no, do not approve

3. Approve for 12 months.

Turner's Syndrome:

1. Is the diagnosis confirmed by genetic testing?

If yes, continue to #2

If no, do not approve

2. For members over 12 years of age, is there evidence of non-closure of epiphyses confirmed by X-ray?

If yes, continue to #3

If no, do not approve

3. Approve for 12 months.

Pre-transplant chronic renal insufficiency:

1. Has the member's nutritional status been optimized and metabolic abnormalities (e.g. metabolic acidosis) been corrected?

If yes, continue to #2

If no, do not approve

2. For members over 12 years of age, is there evidence of non-closure of epiphyses confirmed by X-ray?

If yes, continue to #3

If no, do not approve

3. Approve for 12 months.

Renewal criteria:

1. Does the member meet **ALL** of the following criteria:

a. Evidence of GV greater than 2.5 cm/year, **AND**

b. For members over 12 years old, non-closure of epiphyses confirmed by X-ray, **AND**

c. Bone age suggests has not reached height potential defined as bone age for male has not exceed 16 years of age (required annually when chronological age reaches 15) and bone age for female has not exceed 14 years of age (required annually when chronological age reaches 13).

If yes, approve for 12 months.

If no, do not approve.

Generic Name Herpes Zoster Vaccine

Brand Name Zostavax Vaccine

Created: 1/8/2016

1. Is the member age 60 or older?

 If yes, approve for 1 dose.

 If no, do not approve for not medically
 necessary*

* ACIP/CDC Guidelines (updated 8/22/14) recommend vaccination for patients age 60 and above despite FDA approval for age 50 and above. This recommendation is based on likely waning efficacy of the vaccination over time and lack of long term evidence and no information on revaccination. ACIPD/CDC projects vaccination at age 60 offers the maximum benefit to patients and also the most cost-effective outcomes overall. The latest update makes no mention for special considerations for immunocompromised or other unique populations. However, the update does state “adults receiving the vaccine before age 60 years might not be protected when their risks for herpes zoster and its complications are highest.”

High Risk in Elderly Meds (PA req age \geq 65)

Generic Names: CHLORZOAZONE, CLONAZEPAM, CYPROHEPTADINE, DIGOXIN TAB 250 MCG (0.25 MG) DISOPYRAMIDE, ESTRADIOL, GUANFACINE, INDOMETHACIN, MEGESTROL ACETATE, METHYLDOPA, TICLOPIDINE, TRIHEXYPHENIDYL, BENZTROPINE, ZOLPIDEM, CHLORPHENIRAMINE, DEXBROMPHENIRAMINE, DIPHENHYDRAMINE, GLYBURIDE, NIFEDIPINE IR, ARMOUR THYROID, PHENOBARBITAL, METHYLPHENIDATE HCL, NITROFURANTOIN

Created: 5/11/15

Revised: 7/30/15

Criteria:

1. Is age greater than or equal to 65?
If yes, continue to #2. If no, criteria do not apply.

2. Is the member's diagnosis covered under the Oregon Health Plan according to the Prioritized List of Health Services?
If yes, continue to #3. If no, do not approve

3. Is there sufficient clinical rationale for use of the high risk medication such as clear benefits outweighing increased risks?
If yes, continue to #4. If no, deny exclusion.

4. Has the member failed at least 2 non-high risk alternatives **OR** there are no appropriate alternatives to offer (failure of 1 still required if 1 alternative available)?
If yes, continue to #5. If no, deny for PA criteria not met

5. Approve x life.

Generic Name Histrelin

Brand Name Supprelin LA

Revised: 5/12/10, 03/10/16

Reviewed: 12/2/11, 9/13/12, 9/12/13

1. Does the member have a diagnosis of central precocious puberty?
If yes, continue to #2. If no, continue to #4.
2. Is the member age less than 11 for females and 12 for males?
If yes, continue to #3. If no, do not approve.
3. Are injectable depot medications (such as Lupron) contraindicated for this member or after such medications have been tried do complications preclude further use?
If yes, approve for 12 months with a quantity limit of one per year. If no, do not approve
4. Is the request for use in delaying the onset of puberty and/or continued pubertal development in a child or adolescent with a diagnosis of gender dysphoria?
If yes, continue to #5 If no, do not approve.
5. Has the member reached Tanner stage 2, with documentation that the first physical changes of puberty have occurred?
If yes, continue to #6 If no, do not approve.
6. Is there documentation that the member has had a comprehensive mental health evaluation and has fulfilled eligibility and readiness criteria?
If yes, continue to #7 If no, do not approve.
7. Are injectable depot medications (such as Lupron) contraindicated for this member or after such medications have been tried do complications preclude further use?
If yes, approve until age 18 with a quantity limit of one per year. If no, do not approve

Generic Name	Imiquimod
Brand Name	Aldara, Zyclara

Created: 8/1/11
 Revised: 7/13/12, 8/14/14
 Reviewed: 9/12/13

1. Does the member have a diagnosis of actinic keratoses?
 If yes, do not approve. If no, continue to #2.
2. Does the member have a diagnosis of external condyloma acuminatum (genital warts)?
 If yes, continue to #4. If no, continue to #3.
3. Does the member have a diagnosis of superficial basal cell carcinoma on trunk, neck, or extremities?
 If yes, approve x 12 weeks. If no, continue to #5 .
4. Has the member tried podofilox soln?
 If yes, approve x 4 months. If not, do not approve and recommend podofilox soln.
5. Does the member have a diagnosis of anal intraepithelial neoplasia?
 If yes, approve x 4 months. If no, do not approve.

Insulin Pens

Generic Name	Insulin Lispro Insulin Lispro Protamine and Insulin Lispro Insulin Aspart Insulin Aspart Protamine and Insulin Aspart Insulin Regular Insulin NPH Insulin NPH and Insulin Regular	
Brand Name	Humalog Pen Humalog Pen 75/25 Humulin 70/30 Kwikpen Novolog Penfill Novolog Mix 70/30 Penfill Novolin R InnoLet Novolin N Innolet Novolin 70/30 Innolet	Humalog Kwikpen (including 200 unit) Humalog 75/25 Kwikpen Novolog Flexpen Novolog Mix 70/30 Flexpen Novolin R Penfill Novolin N Penfill Novolin 70/30 Penfill

Created: 1/5/09

Revised: 4/6/09, 9/19/11, 6/1/14, 3/1/17

Reviewed: 9/13/12, 7/15/13, 9/12/13

1. Does the member have diabetes mellitus (Type I and Type II) and require Insulin therapy?

If yes, continue to #2.	If no, do not approve.
-------------------------	------------------------

2. Is the member under the age of 19?

If yes, approve until age 19.	If no, continue to #3.
-------------------------------	------------------------

3. Does the member meet either one of the following criteria?
 - Member demonstrates an inability to draw insulin from a multidose vial into a syringe documented by provider **OR**
 - Use short acting insulin analogs in intensive multi-dose therapy (i.e. greater than 4 times a day injections) **OR**
 - Member has uncontrolled diabetes due to poor compliance evident by claims history

If yes, approve for life

If no, do not approve.

Generic Insulin Glargine 300 units/mL

Brand Toujeo SoloStar

Created: 3/9/17

1. Does the member have diabetes mellitus (Type I or Type II) and require insulin therapy?
 - If yes, continue to #2.
 - If no, do not approve.

2. Is the member over age 18?
 - If yes, continue to #3.
 - If no, do not approve. Toujeo should not be used in children. Recommend Basaglar.

3. Is the request based on the units/day of basal insulin?
 - If yes, evaluate based on a-c.
 - If no, continue to #4.
 - a. Member takes ≤ 80 units of basal insulin per day
 - i. If yes, do not approve. Recommend Basaglar.
 - b. Member takes >80 units/day but ≤ 200 units/day of basal insulin
 - i. If yes, approve for lifetime
 - c. Member takes > 200 units/day of basal insulin?
 - i. If yes, do not approve. Toujeo was not studied in patients with insulin resistance (total daily insulin dose >200 units/day) and is not intended to be a replacement for those requiring U-500 insulin.

4. Does the member have a failure of or contraindication to Basaglar? Failure requires HbA1c not at goal after 3 months of basal insulin therapy.
 - If yes, approve for lifetime.
 - If no, continue to #5.

5. Does the member have nocturnal hypoglycemia after other interventions have been made to address hypoglycemia?
 - If yes, approve for lifetime.
 - If no, do not approve and recommend Basaglar.

Generic Name: Insulin Human NPH U500 #Humulin #U500

Brand Name: Humulin U500 Pens

Note: Pens preferred vs vials due to risk of waste with vials

Created: 5/11/17

Initial Criteria:

1. Does the member have a diagnosis of diabetes mellitus?
If yes, continue to #2. If no, do not approve.
2. Is it medically safe and appropriate for a U500 product? This edit is bypassable by dispensing pharmacy with proper verification of U500 selection to ensure appropriate product selection. In most situations, total insulin usage should be 200 units or greater.
If yes, approve x life. If no, deny for not medically appropriate.

Generic Name Interferon Alfa-2b
 Pegylated Interferon Alfa-2b
 Pegylated Interferon Alfa-2a
 Interferon Alfa-N3

Brand Name Intron A
 PegIntron
 Pegasys
 Alferon-N

Revised: 4/7/08, 1/4/11, 9/12/13, 01/12/17

Reviewed: 7/12/12

Initial Criteria

1. Is the treatment being prescribed for a type of cancer?
 - a. If yes, continue to #2
 - If no, continue to #6
2. Is the treatment being prescribed by a hematologist or oncologist?
 - If yes, continue to #3.
 - If no, do not approve.
3. Is the treatment supported for the diagnosis in the NCCN guidelines?
 - If yes, continue to #5.
 - If no, continue to #4.
4. Is the treatment being used according to the FDA indication?
 - If yes, continue to #5
 - If no, do not approve.
5. Does the request meet criteria for treatment coverage specified in Guideline Note 12 of the Prioritized List of Health Services, considering treatment of cancer with little or no benefit?
 - If yes, approve for 12 months
 - If no, do not approve.
6. Does the member have a diagnosis of chronic hepatitis B?
 - If yes, continue to #7
 - If no, continue to #16.
7. Is the treatment being prescribed by a hepatologist or gastroenterologist?
 - If yes, continue to #8
 - If no, do not approve.
8. Does the member have decompensated cirrhosis?
 - If yes, do not approve.
 - If no, continue to #9.
9. Does the member have compensated cirrhosis?
 - If yes, continue to #10
 - If no, continue to #11.
10. Is HBV DNA > 2000 IU/ml (10,000 or 10⁴copies/ml)?
 - If yes, continue to #15
 - If no, do not approve.
11. Is the member HBeAg (+)?

Generic Name Interferon alfacon-1

Brand Name Infergen

Created: 09/12/2013

Initial Criteria:

1. Is the member at least 18 years of age?
If yes, continue to #2. If no, do not approve.
2. Is the request for treatment of Chronic Hepatitis C with compensated liver disease?
If yes, continue to #3. If no, do not approve.
3. Is the request for continuation of therapy? (Member is currently (prior 12 weeks) on HCV treatment according to Rx profile)
If yes, continue to #10. If no, continue to #4.
4. Does the member have a history of previous interferon-ribavirin combination treatment? Verify by reviewing member's Rx profile for combination interferon-based hepatitis C drugs (Rebetron, PEG-Intron, Pegasys, interferon-alpha) history. Does not include interferon monotherapy.
If yes, review for medical necessity. If no, continue to #5.
5. Does the member have **any** of the following contraindications to the use of interferon-ribavirin therapy?
 - a. decompensated cirrhosis
 - b. autoimmune hepatitisIf yes, do not approve. If no, continue to #6.
6. Does the member have a detectable HCV RNA (viral load) > 50IU/mL?
If yes, continue to #7. If no, do not approve.
7. Does the member have a documented HCV Genotype?
If yes, continue to #8. If no, do not approve.
8. Has the member failed or have a contraindication/adverse reaction to peginterferon alfa-2a (Pegasys)?
If yes, continue to #9. If no, do not approve.
9. Approve for 16 weeks with the following response:

Continuation of Therapy:

1. Does the member have undetectable HCV RNA OR at least a 2-log reduction (+/- one standard deviation) in HCV RNA measured at 12 weeks?

If yes, continue to #2.

If no, do not approve.

2. Approve as follows.

a. For genotype 1 or 4, approve for an additional 36 weeks or for up to a total of 48 weeks of therapy (whichever is the lesser of the two). (max daily dose=1400mg).

b. For genotype 2 or 3, approve for an additional 12 weeks or for up to a total of 24 weeks of therapy (whichever is the lesser of the two). (max daily dose = 800mg).

c. For HIV co-infection, approve for an additional 36 weeks or for up to a total of 48 weeks of therapy (whichever is the lesser of the two). (max daily dose=1400mg).

Generic Name Interferon Alfa-N3

Brand Name Alferon N

Reviewed: 12/2/11, 7/12/12

Revised: 9/12/13

1. Is the member age 18 years or older?

 If yes, continue to #2.

 If no, do not approve.

2. Does the member have a diagnosis of Condyloma Acuminata?

 If yes, continue to #3.

 If no, do not approve.

3. Has the member tried and failed or have contraindications to **ALL** of the following?

 a. Cryotherapy, and

 b. Trichloroacetic acid, and

 c. Surgical excision, and

 d. Podophyllum resin, and

 e. Podofilox, and

 f. Aldara.

 If yes, approve for 2 months.

 If no, do not approve.

Generic Name Interferon gamma-1b

Brand Name Actimmune

Revised: 6/2/08

Reviewed: 12/2/11, 7/12/12, 9/12/13

1. Does the member have a diagnosis of Chronic Granulomatous Disease or Malignant osteopetrosis?

 If yes, continue to #2. If no, do not approve.

2. Approve for lifetime.

Generic Name Itraconazole capsule
 Itraconazole oral solution

Brand Name Sporanox Capsule
 Sporanox Oral Solution

Revised: 11/21/08, 09/08/16

Reviewed: 12/2/11, 7/12/12, 9/12/13

Initial Criteria:

1. Does the member have **one** of the following diagnoses?
 - a. Blastomycosis, or
 - b. Histoplasmosis, or
 - c. Aspergillosis.

If yes, approve for requested course up to 12 months. If no, continue to #2.

2. Does the member have a diagnosis of onychomycosis?

If yes, continue to #3. If no, continue to #5

3. Does the member meet **both** of the following criteria?
 - a. Member is immunocompromised (drug-induced, HIV, etc) or has diabetes, and
 - b. Member has a history of cellulitis or severe infection or severe functional impairment secondary to onychomycosis.

If yes, continue to #4. If no, do not approve.

4. Has the member tried and failed or have contraindications to terbinafine?

If yes, approve for 3 months If no, do not approve.

5. Does the member have a diagnosis of candidiasis of the mouth and esophagus?

If yes, continue to #6. If no, continue to #8.

6. Is the member immunocompromised?

If yes, continue to #7. If no, do not approve.

7. Has the member failed or have contraindications to fluconazole?

If yes, approve oral solution for 2 weeks If no, do not approve.

8. Does the member have a diagnosis of febrile neutropenia?

If yes, approve for 1 month. If no, do not approve.

Generic Name Intravenous Immune Globulin (IVIg)

Immune Globulin, subcutaneous

Brand Name Carimune NF, Flebogamma, Gamimune N, Gammagard S/D, Gammar IV, Gammar-P IV, Iveegam, Octagam, Panglobulin, Polygam S/D, Venoglobulin, Gammaplex, Bivigam

Hizentra, Hyqvia

Revised: 7/15/10, 12/2/10, 2/15/12, 9/26/12, 9/12/13

Reviewed: 12/2/11, 7/12/12

IVIg may be considered medically necessary for the following conditions:

1. Primary Immunodeficiencies supported by laboratory findings
 - a. Congenital Agammaglobulinemia or X-linked Agammaglobulinemia:
 - i. Deficits or absence of all 5 Ig classes- IgG, IgM, IgA, IgE, IgD
 - ii. Very low or absent B-lymphocytes
 - iii. Normal T lymphocytes
 - iv. The physical examination of members with XLA usually reveals absent lymph nodes and tonsils
 - v. Recurrent bacterial infections
 - vi. Antimicrobials are often required in addition to IVIg or SCIG
 - b. Immune Globulin Subclass Deficiency
 - i. Low IgA, IgG, and IgE with elevated IgM
 - c. UNG (Uracil nucleoside Glycosylase) Deficiency
 - i. Low IgA, IgG, and IgE with elevated IgM
 - d. Hypogammaglobulinemia
 - i. Below normal IgG
 - ii. Recurrent bacterial infections
 - e. ICOS (Inducible T-cell co-stimulator) Deficiency
 - i. Panhypogammaglobulinemia and impaired antibody production and low B-lymphocytes
 - f. Common Variable Immunodeficiency (CVID; Acquired Hypogammaglobulinemia; Adult Onset Hypogammaglobulinemia; Dysgammaglobulinemia)
 - i. Low to normal IgG and inability to produce a response to protein such as tetanus or carbohydrate antigens such as pneumovax, +
 - ii. Severe, recurrent and/or chronic infections

- g. Severe Combined Immunodeficiency (SCID) such as Wiskott-Aldrich Syndrome
 - i. Low IgG, IgA and IgM
 - ii. Absent or below normal B-lymphocytes and T-lymphocytes
 - iii. IVIG or SCIG should be initiated before BMT and afterward as necessary

Approval duration: Lifetime.

2. Immune Thrombocytopenic Purpura (ITP)

a. Acute ITP

- i. Indicated to manage an acute bleeding (platelet < 30,000) episode or increase platelet prior to major, invasive surgery (e.g., splenectomy).

b. Chronic Refractory ITP

- i. Indicated on when all of the following are met:
 - 1. Prior treatment with oral corticosteroids
 - 2. Platelets persistently < 20,000 or symptoms of bleeding

c. ITP in Pregnancy

- i. Women who have previously delivered children with autoimmune thrombocytopenia, or
- ii. Platelet < 30,000 associated with bleeding before vaginal delivery or C-section, or
- iii. Women with platelets < 75,000 during the current pregnancy, or
- iv. Women with history of splenectomy

Approval duration: Up to 3 months.

1. Chronic B-Cell Lymphocytic Leukemia with Hypogammaglobulinemia

- a. IgG < 600
- b. Evidence of specific antibody deficiency + repeated bacterial infections

Approval duration: up to 3 months.

2. HIV

- a. < 13 years old, +
- b. Entry level CD4+ \geq 200/mm³, +
- c. Clinically symptomatic

Approval duration: up to 3 months.

3. Allogeneic Bone Marrow Transplant

- a. hematologic neoplasms +

- b. ≥ 20 years old +
- c. Seropositive for CMV prior to transplant +
- d. Seronegative donor, + for medicare members
- e. Medicare covered transplant

Approval duration: up to 3 months.

4. Kawasaki Disease

- a. IVIG indicated during the 1st 10 days of diagnosis when combined with aspirin to reduce coronary aneurysms. There is no benefit if administered after 10 days from onset of symptoms.
- b. IVIG may be indicated after 10 days in pediatric members with persistent fever without explanation or aneurysms and ongoing systemic inflammation (as denoted by elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) are present.

Approval duration: up to 3 months.

5. Acute & Chronic Demyelinating Polyradiculoneuropathy Including Guillain-Barre Syndrome

- a. Other therapy has failed or is contraindicated + member has difficulty with venous access for plasmaphoresis, or
- b. Rapidly progressive form of disease with symptoms < 2 weeks or deteriorating ability to ambulate, or
- c. Deteriorating pulmonary function tests

6. Myasthenia Gravis

- a. Treatment of acute decompensation such as respiratory failure, or
- b. Other treatments have been unsuccessful or are contraindicated including plasma exchange, prednisone, azathioprine, cyclosporine, and cyclophosphamide

Approval duration: As requested by provider up to 3 months.

7. Autoimmune Mucocutaneous Blistering Disease

- a. One of the following diagnoses, +
 - ii. Pemphigus vulgaris
 - iii. Pemphigus foliaceus
 - iv. Bullous pemphigoid
 - v. Mucous membrane pemphigoid
 - vi. Epidermolysis bullous acquisita
- b. Failed conventional therapy (e.g., steroids, methotrexate, other immunosuppressant) or conventional therapy is contraindicated, or

- c. Have rapidly progressive disease in which a clinical response could be affected quickly enough using conventional agents. IVIG should be administered only until conventional agents take effect.

Approval duration: As requested by provider up to 3 months.

8. Autoimmune Hemolytic Anemia, Warm Type

- a. Predominance of IgG antibodies (as opposed to predominance of IgM)
- b. Members \leq 18 years + hepatomegaly or hepatosplenomegaly

Approval duration: As requested by provider up to 3 months.

9. Polymyositis and Dermatomyositis

- a. Unresponsive to or intolerant of steroids, azathioprine, cyclosporine, and cyclophosphamide
- b. Associated with severe disability

Dose: 2gm/kg/month up to 3 months. Records must show measurable, objective response within 3 months of initiation such as improvement in CPK levels, increase or stabilization of muscle strength, or EMG abnormalities.

Approval duration: Up to 3 months.

12. Multifocal motor neuropathy (MMN)

Approve x 3 months. Records must document response such as improvement in functional ability, such as grip strength.

Approval duration: 3 months. Records must document response such as improvement in functional ability, such as grip strength for renewal request.

Generic Name Ivabradine

Brand Name Corlanor

Created: 6/25/15

Initial:

1. Does the member have a diagnosis of stable, symptomatic chronic heart failure?

If yes, continue to #2

If no, do not approve.

2. Is the patients ejection fraction $\leq 35\%$?

If yes, continue to #3

If no, do not approve.

3. Is the member's resting heart rate at least 70 beats per minute?

If yes, continue to #4

If no, do not approve

4. Is the member on maximum tolerated doses of ALL of the following classes (formulary options of evidence supported medications and max doses shown)?

a) Beta-Blocker [metoprolol succinate (200mg/day), carvedilol (25mg twice daily)]

b) ACE-i/ARB [captopril (50mg three times daily), enalapril (10mg twice daily), lisinopril (20-40mg/day), ramipril (5mg twice daily), losartan (150mg/day)],

c) Mineralcorticoid receptor antagonist [spironolactone (25 mg/day)]

If yes, approve x life

If no, deny for criteria not met

If yes, continue to #8.

If no, do not approve.

8. Is the member on all of (or have contraindication to) the following and compliant for at least 6 months?

- Pulmozyme, AND
- nebulized hypertonic saline, AND
- inhaled or oral antibiotics (if appropriate, such as pseudomonas positive)

If yes, approve for 3 months.

If no, do not approve.

Renewal Criteria:

1. Has the member shown compliance with fill history?*

If yes, continue to #2.

If no, review case
with Medical Director.

2. Did the member demonstrate a documented objective response by one of the following?

- A lack of decline in FEV1 verified with documentation
- A reduction in the incidence of pulmonary exacerbations
- A significant improvement in BMI by 10% from baseline

If yes, approve for 3 months

If no, do not approve.

Generic Name: Ixekizumab

Brand Name: Taltz

Created: 07/19/16

Plaque Psoriasis:

Initial Criteria:

1. Does the member have active, chronic, moderate to severe Plaque Psoriasis at baseline meeting both criteria of Guideline Note 21:
 - a. Causing functional impairment (inability to use hands or feet or significant facial involvement preventing normal social interaction)
 - b. Affecting $\geq 10\%$ of the body and/or hand, foot, mucous membrane involvementIf yes, continue to #2. If no, do not approve.
2. Has the treatment been prescribed or is it currently being supervised by a dermatologist?
If yes, continue to #3. If no, do not approve.
3. Has the member tried and failed Humira or have contraindications to TNF inhibitors?
If yes, continue to #4. If no, do not approve
4. Approve for 6 months for induction and 80 mg Q4 week maintenance.

Renewal criteria:

1. Has the member experienced a 50% improvement in affected body surface area, plaque severity and/or functioning?
If yes, approve for 12 months If no, do not approve.

Generic Name Lansoprazole

Brand Name Prevacid, First-Lansoprazole

Revised: 7/14/09, 7/6/11, 9/19/11, 9/26/12, 9/12/13, 12/26/14, 11/6/15

1. Is the member's age less than 19?

If yes, continue to #5

If no, continue to #2.

2. Is the diagnosis GERD?

If yes, continue to #3

If no, continue to #4

3. Does the request meet at least ONE of the following?:

a.) Continuation of PPI therapy beyond 8 weeks (including other PPIs)?

OR

b). The request for more than 8 weeks or unspecified duration?

If yes, deny. Chronic GERD therapy
not covered per Guideline Note #144.

If no, continue to #5.

4. Does the member have a documented and medically appropriate diagnosis which is currently funded by the Oregon Health Plan (OHP) Prioritized List?

If yes, continue to #5.

If no, deny.

5. Is the request for oral capsules)?

If yes, continue to #8.

If no, continue to #6.

6. Is the member unable to swallow pills **or** does the member require drug administration through a G-tube or NG-tube?

If yes, continue to #7.

If no, do not approve.

7. Has the member failed ALL of the following?

a. cimetidine liquid or ranitidine syrup AND

b. omeprazole suspension or (First-omeprazole)

If yes, approve First-Lansoprazole.

If no, do not approve

8. Has the member tried and failed prescription omeprazole AND pantoprazole?

If yes, continue to #9.

If no, do not approve.

9. Approve with the following durations:

- Kids: approve until age 19.
- Adults with a covered diagnosis (not GERD): max 12 months

Adults with GERD: 8 weeks.

8. Is the request for Lupaneta or is norethindrone add-back therapy also prescribed?
If yes, approve for 6 months. If no, do not approve.
9. Does the member have a diagnosis of uterine leiomyoma (fibroids)?
If yes, approve for 3 months. If no, continue to #10.
10. Does the member have a diagnosis of central precocious puberty?
If yes, continue to #11. If no, continue to #12.
11. Is the member age less than 11 for females and 12 for males?
If yes, approve for 12 months. If no, do not approve.
12. Is the request for use in delaying the onset of puberty and/or continued pubertal development in a child or adolescent with a diagnosis of gender dysphoria?
If yes, continue to #13. If no, do not approve.
13. Has the member reached Tanner stage 2, with documentation that the first physical changes of puberty have occurred?
If yes, continue to #14. If no, do not approve.
14. Is there documentation that the member has had a comprehensive mental health evaluation and has fulfilled eligibility and readiness criteria?
If yes, approve until age 18. If no, do not approve.

Generic Name Mecasermin

Brand Name Increlex

Revised: 11/21/08, 9/12/13

Reviewed: 12/2/11, 9/13/12

Initial Criteria:

1. Is the member age 2-18 years old?
If yes, continue to #2
If no, do not approve.
2. Is the prescriber a pediatric endocrinologist?
If yes, continue to #3.
If no, do not approve.
3. Does the member have primary IGF-1 deficiency due to growth hormone insensitivity syndrome?
If yes, continue to #5.
If no, continue to #4.
4. Does the member have a growth hormone gene deletion and has developed neutralizing antibodies to growth hormone?
If yes, continue to #5.
If no, do not approve.
5. Have secondary causes of IGF-1 deficiency been ruled out, such as growth hormone deficiency, malnutrition, hypothyroidism, or chronic corticosteroid therapy?
If yes, continue to #6.
If no, do not approve.
6. Is there evidence of non-closure of the epiphyseal plate?
If yes, continue to #7.
If no, do not approve.
7. Does the member have a suspected neoplasia?
If yes, do not approve.
If no, continue to #8.
8. Approve for 12 months.

Renewal Criteria:

1. Does the member meet **ALL** of the following criteria:
 - a. Evidence of GV greater than 2.5 cm/year, **AND**
 - b. Non-closure of epiphyses confirmed by X-ray, **AND**
 - c. Bone age suggests that height potential has not been achieved defined as bone age for male has not exceeded 16 years of age (required annually when chronological age reaches 15) and bone age for female has not

exceeded 14 years of age (required annually when chronological age reaches 13)

If yes, approve for 12 months.

If no, do not approve.

Renewal Criteria:

1. Has the member maintained cognitive and functional ability or has there been a reduction in the rate of cognitive and functional decline?
If yes, approve for 12 months. If no, do not approve.

Discontinuation: Namenda should be discontinued if there is no clinical benefit after 6 months; if the member is institutionalized and/or when the member becomes dependent on others for all activities of daily living.

Generic Name: Mepolizumab

Brand Name: Nucala

Created: 3/21/16

*****Non-formulary on pharmacy benefit*****

Initial Criteria:

1. Is Nucala being requested by a pulmonologist?
If yes, continue to #2. If no, do not approve.
2. Is the member ≥ 12 years?
If yes, continue to #3. If no, do not approve.
3. Does the member have a diagnosis of moderate to severe asthma with an eosinophilic phenotype?
If yes, continue to #4. If no, do not approve.
4. Is the member a current smoker?
If yes, do not approve. If no, continue to #5.
5. Is the member's recent eosinophil count of ≥ 300 cells/mcL OR a baseline of >150 cells/mcL?
If yes, continue to #6. If no, do not approve.
6. Has the member failed the following agents including as combination therapy:
 - a. High dose inhaled corticosteroid with a Long acting beta agonist (such as Advair, Symbicort)
 - b. Long acting muscarinic antagonist (such as Spiriva)
 - c. Leukotriene inhibitor (such as montelukast)If yes, continue to #7. If no, do not approve.
7. Is the member currently on Xolair and intent is to continue Xolair while on Nucala?
If yes, do not approve If no, continue to #8
8. Does the member have a history of compliance with asthma medications (above)?
If yes, approve x 6 months. If no, do not approve

Renewal Criteria:

1. Has the member had a reduction in asthma exacerbations necessitating frequent office visits, ED / urgent care visits, hospitalizations, oral steroids and demonstrated sustained clinical improvement from baseline while on Nucala?

If yes, approve for 6 months

If no, do not approve.

Generic Name Midostaurin

Brand Name Rydapt

Created: 07/13/17

Initial Criteria

1. Is the treatment being prescribed by a hematologist or oncologist for a type of cancer?
If yes, continue to #2. If no, continue to #5.
2. Is the treatment supported for the diagnosis in the NCCN guidelines?
If yes, continue to #4. If no, continue to #3.
3. Is the treatment being used according to the FDA indication?
If yes, continue to #4. If no, do not approve.
4. Does the request meet criteria for treatment coverage specified in Guideline Note 12 of the Prioritized List of Health Services, considering treatment of cancer with little or no benefit?
If yes, approve for 12 months. If no, do not approve.
5. Is the treatment being prescribed by a hematologist, oncologist, or immunologist?
If yes, continue to #6. If no, do not approve.
6. Does the member have a diagnosis of aggressive systemic mastocytosis (ASM)?
If yes, continue to #7. If no, continue to #9.
7. Is the aggressive systemic mastocytosis without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown?
If yes, continue to #8. If no, continue to #10.
8. Has the member failed imatinib?
If yes, continue to #10. If no, do not approve and offer imatinib.
9. Does the member have systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)?
If yes, continue to #10. If no, do not approve.
10. Approve for 6 months.

Renewal Criteria

Cancer:

1. Is there evidence of tumor response and resolution or improvement of disease-related signs and symptoms?

If yes, approve for 12 months.

If no, do not approve.

Renewal Criteria

Systemic Mastocytosis:

1. Is there documentation of a positive hematological response?

If yes, approve for 12 months.

If no, do not approve.

Generic Name: Miltefosine

Brand Name: Impavido

Created: 7/19/16

1. Is the request for treatment of visceral, cutaneous, and/or mucosal leishmaniasis?
If yes, continue to #2. If no, deny.
2. Is the request from or in consultation with an Infectious Disease specialist?
If yes, continue to #3. If no, deny.
3. Has the member tried and failed IV amphotericin B or Ambisome?
If yes, approve for maximum 28 days If no, deny.

MIGRAINE TREATMENTS

Generic Name Sumatriptan
 Naratriptan
 Rizatriptan
 Zolmitriptan
 Dihydroergotamine

Brand Name Imitrex
 Amerge
 Maxalt
 Zomig
 Migranal

Created: 12/14/09

Revised: 9/28/11, 1/22/16

Reviewed: 9/13/12, 9/12/13

Quantity Limit Explanation:

According to product labeling, the safety and effectiveness of treating more than 4 headaches in a 30-day period with sumatriptan (oral and nasal spray), naratriptan, rizatriptan, frovatriptan, almotriptan, and zolmitriptan nasal spray have not been established.

Medical Necessity Quantity exception criteria:

1. Is the request for more than 4 treatment days per month?

 If yes, do not approve and recommend reevaluation of migraine prophylaxis.

Prophylaxis indications:

- a. 2 or more attacks per month that produce disability that lasts 3 or more days per month
- b. Contraindication or failure of acute treatments
- c. Use of abortive medication more than twice per week
- d. Presence of uncommon migraine (hemiplegic migraine, prolonged aura, migrainous infarction).¹

Common prophylactic medications for migraine include:

- a. Beta blockers: propranolol
- b. Calcium channel blockers: verapamil
- c. Tricyclic antidepressants: amitriptyline, nortriptyline
- d. Divalproex sodium
- e. Topiramate

Generic Name Montelukast

Brand Name Singulair

Revised: 4/11/08

Reviewed: 12/2/11, 9/12/13

1. Does the member have a diagnosis of Asthma?

 If yes, continue to #2.

 If no, do not approve.

2. Approve for lifetime.

Generic Name: Naltrexone Extended-Release Injection

Brand Name: Vivitrol

Revised: 8/5/08, 01/13/11, 9/12/13, 12/21/15

Reviewed: 9/13/12

***** Nonformulary on outpatient benefit. PA required for medical benefit. *****

Initial Criteria:

1. Does the member have a diagnosis of alcohol dependence ?
If yes, continue to #3. If no, continue to #2.
2. Does the member have a diagnosis of opioid dependence ?
If yes, continue to #5. If no, do not approve.
3. Has the member failed an adequate trial of oral naltrexone?
If yes, continue to #6 If no, go to #4.
4. Has the provider established a case for clear cost-avoidance with Vivitrol due to a number of repeat hospitalizations for the member from their alcohol dependence AND a trial of oral naltrexone has been determined not appropriate?
If yes, continue to #6 If no, do not approve
5. Has the member failed a trial of the following?
 - a. Oral naltrexone

AND

 - b. Opioid based therapy (one of the following)
 - i. MMT from a Federally Certified Medical Methadone Maintenance Clinic

OR

 - ii. Suboxone

If yes, continue to #6 If no, do not approve.
6. Is there documentation that the member is engaged in a drug and alcohol treatment program with psychosocial support?
If yes, approve X 6 months If no, do not approve.

Renewal Criteria:

Has the member maintained abstinence with the use of Vivitrol based on negative blood or urine toxicology screens, OR maintained ongoing participation in a comprehensive substance abuse program that includes psychosocial support?

If yes, approve x 6 months. If no, continue to #2

1. Is there evidence of significantly reduced utilization of acute care services (ED visits, inpatient, and/or detox services)?
If yes approve x 6 months If no do not approve.

Notes to Provider:

- FDA-Approved Indication: treatment of alcohol dependence in members who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with naltrexone injection.
- **Member should be abstinent from alcohol and opioids for a minimum of 7 days prior to receiving Vivitrol.**
- Efficacy promoting abstinence has not been demonstrated in members who have not completed detoxification and achieved alcohol abstinence prior to beginning Vivitrol treatment.
- Use of naltrexone in combination with other anti-alcoholic medications is not recommended.
- Acute hepatitis, acute liver disease or significant renal impairment are typically contraindications for Vivitrol.

Dosing and Admin: 380 mg IM into the upper outer quadrant of a gluteal muscle, alternating buttocks, every 4 weeks.

Nasal Corticosteroids

Generic Name	Beclomethasone Budesonide Flunisolide Fluticasone Mometasone Triamcinolone
Brand Name	Beconase AQ, Rhinocort AQ, Nasarel, Nasalide, Flonase, Nasonex, Nasacort AQ Nasacort 24 hr OTC

Revised: 12/21/09, 9/19/11, 9/12/13

Reviewed: 5/10/12

Note: Fluticasone and Flunisolide are available with ST to asthma medications. Nasacort 24hr OTC is available with Step Therapy off fluticasone (fluticasone criteria also apply).

1. Does the member have a diagnosis of chronic sinusitis?
If yes, continue to #5. If no, continue to #2.
2. Does the member have a diagnosis of allergic rhinitis?
If yes, continue to #3. If no, do not approve.
3. Does the member have any of the following complications?
 - a. Periorbital inflammation or other ocular complications (chronic eye swelling)
 - b. History of sinus surgery or frequent sinus procedures (e.g. fistula drainage)
 - c. Wegener's GranulomatosisIf yes continue to #5. If no, continue to #4
4. Does the member have a diagnosis of asthma?
If yes, continue to #5. If no, do not approve
5. Approve generic fluticasone (Flonase) or generic flunisolide 29mcg (Nasarel) or generic flunisolide 0.025% (Nasarel) for life. If request for Nasacort 24 Hr OTC and fluticasone failed, approve for life.

Generic Name Natalizumab

Brand Name Tysabri

Revised: 5/19/10, 9/12/13, 06/15/15

Reviewed: 12/2/11

****Non-formulary on pharmacy benefit. This is considered a medical benefit covered drug****

Initial Criteria (Multiple Sclerosis):

1. Is the member ≥ 18 years old and has a diagnosis of relapsing-remitting multiple sclerosis?

If yes, continue to #2.

If no, do not approve.

2. Is treatment requested by or in consultation with a neurologist?

If yes, continue to #3.

If no, do not approve.

3. Has the member failed* or have contraindications to treatment **with one of the following?**

a. Interferon beta (Avonex, Rebif, Plegridy, Extavia or Betaseron)

OR

b. Glatiramir acetate (Copaxone, Glatopa), Teriflunomide (Aubagio)

*Note: For treatment failure, all of the following must be documented in the medical record:

1. Member compliance with previous regimens

2. Continuation of clinical relapses **or** CNS lesion progression on MRI **or** worsening disability

If yes, continue to #4.

If no, do not approve.

4. Has the member failed* or have contraindications to treatment with one of the following:

a. Fingolimod (Gilenya)

b. Dimethyl Fumarate (Tecfidera)

*Note: For treatment failure, all of the following must be documented in the medical record:

i. Member compliance with previous regimens

ii. Continuation of clinical relapses **or** CNS lesion progression on MRI **or** worsening disability

If yes, continue to #5.

If no, do not approve.

5. Is Tysabri intended to be used concurrently with any of the following:

- a. Interferon beta (Avonex, Plegridy, Rebif or Betaseron)
- b. Glatiramir acetate (Copaxone)
- c. Fingolimod (Gilenya), Teriflunomide (Aubagio), Dimethyl Fumarate (Tecfidera)

If yes, do not approve.

If no, continue to #5.

Combination therapy is not
FDA approved and increases
risk of PML.

6. Approve natalizumab 300 mg infusion once a month for 12 months.

Renewal Criteria (MS):

1. Is there documentation of benefit since initiation of Tysabri, such as delay in the accumulation of physical disability and/or reduction in the frequency of clinical exacerbations and no symptoms suggestive of PML ?

If yes, approve x 12 months.

If no, do not approve.

Initial Criteria (Crohn's Disease):

1. Does the member have a diagnosis of moderate to severe Crohn's disease?

If yes, continue to #2.

If no, do not approve.

2. Does the member have an elevated baseline C reactive protein (CRP) level > 2.87ml/L?

If yes, continue to #3.

If no, do not approve.

3. Has the member failed or have contraindications to treatment with an adequate course of systemic corticosteroids at a prednisone equivalent of 40-60mg/day?

If yes, continue to #4.

If no, do not approve.

4. Has the member demonstrated treatment failure (e.g. active disease flares while stabilized for at least 2 months) or contraindications to all of the following:

- a. Azathioprine
- b. Mercaptopruine
- c. Cyclosporine
- d. Methotrexate
- e. Remicade
- f. Humira

If yes, continue to #5.

If no, do not approve

5. Is Tysabri being prescribed as monotherapy or with either oral steroids or 5-Aminosalicylates (e.g. Asacol, Rowasa, Pentasa)?

If yes, continue to #6.

If no, do not approve.

6. If the member is currently on oral steroids, does the provider have a taper schedule outlined for as soon as the member experiences clinical response?

If yes or not applicable, continue to #7. If no, do not approve.

7. Approve x 6 months.

Renewal Criteria (Crohn's disease):

1. Is there demonstration of clinical response evidenced by at least one of the following:

- a. Reduction in CDAI or number of disease flares or improved quality of life
- b. If previously on oral steroids, they have been successfully discontinued
- c. No history of serious prior infection or evidence of liver toxicity since the previous authorization

If yes, approve x 12 months.

If no, do not approve.

Somatostatin Analogs

Generic Name	Octreotide Octreotide acetate Lanreotide Pasireotide diaspertate Pasireotide
Brand Name	Sandostatin Sandostatin LAR Somatuline Signifor Signifor LAR

Created: 03/09/17

*****Depot products nonformulary for outpatient benefit. PA required on medical benefit.*****

Initial Criteria:

1. Is the request prescribed by or supervised by an endocrinologist?
If yes, continue to #2
If no, continue to #8.
2. Is the request for Signifor LAR?
If yes, continue to #6.
If no, continue to #3.
3. Is the request for Signifor?
If yes, continue to #4.
If no, continue to #6.
4. Is the request for the treatment of Cushing's Disease?
If yes, continue to #5.
If no, continue to #6.
5. Is pituitary surgery is not an option or has it not been curative?
If yes, approve for 3 months.
If no, do not approve.
6. Does the member have a diagnosis of acromegaly confirmed by elevated IGF-1 levels?
If yes, continue to #7.
If no, continue to #8.
7. Is the acromegaly moderate to severe or symptomatic?
If yes, continue to #8.
If no, do not approve.
8. Does the member have persistent disease after surgery or considered not to be a candidate for surgery?
If yes, continue to #13.
If no, do not approve.

9. Is the treatment being prescribed by an oncologist for a type of cancer?
If yes, continue to #10. If no, do not approve.
10. Is the treatment supported for the diagnosis in the NCCN guidelines?
If yes, continue to #12. If no, continue to #11.
11. Is the treatment being used according to the FDA indication?
If yes, continue to #12. If no, do not approve.
12. Does the request meet criteria for treatment coverage specified in Guideline Note 12 of the Prioritized List of Health Services, considering treatment of cancer with little or no benefit?
If yes, continue to #17. If no, do not approve.
13. Is the request for octreotide or octreotide LAR?
If yes, continue to #17. If no, continue to #14.
14. Is the request for Somatuline?
If yes, continue to #15. If no, continue to #16.
15. Has the member tried and failed or have a contraindication to octreotide?
If yes, continue to #17. If no, do not approve and offer octreotide.
16. Has the member tried and failed or have a contraindication to Sandostatin/Sandostatin LAR AND Somatuline?
a. If yes, continue to #17. If no, do not approve and offer all untried agents.
17. Approve for 12 months.

Renewal Criteria:

1. Does the member have Cushing's Disease?
If yes, continue to #2. If no, continue to #3.
2. Has the member had a response of at least a 50% reduction in normalization of mean 24 hour urine-free cortisol?
If yes, approve for life. If no, do not approve.
3. Does the member have acromegaly?
If yes, continue to #4. If no, continue to #5.

4. Has the member had a reduction in or has reached a target goal of GH or an age-normalized serum IGF-1 value?
If yes, approve for 12 months. If no, do not approve.
5. Does the member have a cancer diagnosis?
If yes, continue to #6. If no, do not approve.
6. Has the member reached treatment goals such as:
- Symptom control, such as reduction in diarrhea episodes or carcinoid symptoms
 - Tumor control and disease stabilization
- If yes, approve for 12 months. If no, do not approve.

Opioids PA criteria

Updated: 1/9/17

The following criteria apply to all reviews including PA required, Quantity limit exceeded, and formulary exception.

Representative Brand Names: Oxycontin, Duragesic, MS Contin, Dilaudid, Vicodin, Norco, Opana ER, Avinza

Representative Generic Names: oxycodone, morphine, fentanyl, hydromorphone, codeine, hydrocodone/AAP

New Quantity Limit for IR opioids criteria belongs further below.

ALL (new start and renewal)

1. Is the diagnosis funded for coverage under Oregon Medicaid Prioritized List of Health Services?; And does Practice Guideline Note #60 apply?:

- a. Straight Above-The-Line (no applicable guideline notes)=>continue to #3
- b. Pairs to Lines Where Guideline Note #60 (Opioid Prescribing for Back Pain) => continue to #2
- c. Straight Below-The-Line=> Deny

2. Does the request meet Guideline Note #60 for Opioid Prescribing for Low Back Pain?

ALL sub-provisions (i, ii, etc) must be met for a) or b) or c) as applicable by timing of use of opioids related to onset of pain/injury:

- a) Acute First 6 weeks:
 - i. Immediate-Release opiate only
 - ii. Non-opiates such as NSAIDs, APAP, muscle relaxants failed
 - iii. Using other active interventions such as physical therapy
 - iv. No current or history of opiate abuse.
- b) Acute 6 weeks to 90 days:
 - i. All of the above from section “a) Acute First 6 weeks”
 - ii. Demonstrated functional improvement by validated tools from first 6 weeks (see questions 8-10 below to assist evaluation)
 - iii. Assessment of risk of opioid abuse (see questions 8-10 below to assist evaluation)
- c) Chronic (beyond 90 days)
 - i. Member established on therapy of requested product prior to last 90 days. Members who initiated therapy in last 90 days (sections a and b above) will not be approved to continue into chronic use.
 - ii. Documentation that a taper plan is in place to discontinue opiates by 1/1/2018. Taper plan itself is not required for submission so long as provider documents such a plan is in place.

If yes, continue to #3.

If no, deny for Guideline Note #60
Not met.

3. Has CareOregon previously approved this opioid?

If yes, continue to #5

If no, continue to #4.

New Starts

4. Are the following clinical/quality/preferred alternatives met?

- Diagnosis not migraine
- Not on dual long acting opiates (including methadone)
- Have preferred alts been tried and failed? (may not apply to all requests)
 - Oxycotin or Fentanyl: failure of morphine ER tablets (generic MS Contin)
 - Non-formulary meds: assess appropriateness of formulary alts at the discretion of the plan.

If yes, continue to #11.

If no, deny.

Renewal Criteria

5. Does the member have active cancer pain or is the member in a palliative care program?

If yes, continue to #11.

If no, continue to #6.

6. Has the member experienced an overdose event in the last year, including ED or hospitalization?

If yes, deny

If no, continue to #7

7. Has the member tried and failed non-medication modalities (failure: experienced little to no improvement in function or quality of life) Or is there a reason as to why member cannot participate in these activities?

If yes, continue to #8

If no, deny

8. Has the member's function improved while using opioids? This should include ONE of the following:

- PEG questionnaire
- FRQ questionnaire
- PDI (Pain Disability Index)
- Clear documentation of physician assessment of changes from baseline function.

If yes, continue to #9.

If no, deny

9. Has the member's risk been assessed? This should include documentation of ALL of the following:

- Validated risk scoring tool such as ORT, CAGE-AID, SOAPP-R, COMM, DIRE, ORS, and AUDIT
- PDMP report

- Mental Health Screening such as PHQ-9, GAD-7, PC-PTSD, or mental health professional evaluation
- UDS

If yes, continue to #10.

If no, deny

10. Are either of the following met?:

- a) UDS NOT consistent with what is prescribed; **or**
- b) PDMP report shows signs of fraud, waste, or abuse.

If yes, deny.

If no, continue to #11

11. Approve durations (assume above met):

- Straight Above-The-Line (no applicable guideline notes): 12 months with renewal criteria
- Acute Use, Pairs to Lines Where Guideline Note #60 (Opioid Prescribing for Back Pain):
 - Initial: 6 weeks
 - Renewal: additional 6 final weeks
- Chronic Use Per Guideline Note #60: 12 months OR 1/1/2018, whichever is earliest.
 - Durations may need to be reduced to coincide with CCO MED reduction efforts

QL Exception Criteria- for QLs based on 120 MED

Prescriptions written for “as needed” doses will require clear documentation of expected number of max tablets per day written in order to be reviewed for prior authorization.

First QL PA

1. Does member have active cancer pain or use for palliation/terminal care?

Yes, approve x life.

No, continue to #2.

2. Is member established on therapy?

Yes, continue to #3.

No, deny for not medically appropriate.

3. Does the member have a diagnosis of chronic back pain (dx pairs to GN 60) OR is straight BTL?

Yes, continue to #4

No, continue to # 5

4. Is there documentation of plan to taper off opioids by end of 2017?

Yes, approve x 6 months.

No, deny for GN/BTL.

5. Is there a documented taper plan to taper below MED 120 in 6 months?

Yes, approve x 6 months.

No, deny for not medically appropriate.

Renewal for QL

1. Is diagnosis of chronic back pain (dx pairs to GN 60) OR is straight BTL?

Yes, continue to #2.

No, continue to #3

2. Has member demonstrated a taper from last approval AND plan to continue taper to be off by end of 2017?

Yes, approve until end of 2017.

No, deny for GN/BTL.

3. Is there a medical reason the member has not been successful to taper below MED 120 in last 6 months? Reasons may include acute pain such as severe fracture OR extremely high MED dose originally with continued successful taper but still above MED 120.

Yes, approve x 6 months.

No, deny for not medically appropriate.

Brand Name Ciprodex Otic

Generic Name Ciprofloxacin/dexamethasone

Revised: 1/22/10, 2/14/12

Reviewed: 9/13/12, 9/12/13

1. Is the diagnosis Acute Otitis Externa (AOE)?
If yes, continue to #2. If no, continue to #4.
2. Has the member failed treatment with neomycin/polymyxin B/HC otic?
If yes, continue to #6. If no, continue to #3.
3. Does the member have a perforated tympanic membrane or tympanostomy tubes?
If yes, continue to #6. If no, do not approve
4. Does the member have a diagnosis of Chronic Suppurative Otitis Media (CSOM)?
If yes, deny for below the line diagnosis. If no, continue to #5.
5. Is the diagnosis Acute Otitis Media with tympanostomy tubes (AOMT) or post-operative tympanostomy tube otorrhea and/or granulation tissue?
If yes, approve #1 bottle (7.5ml) for 7 days. If no, continue to #8.
6. Has the member failed a trial of ofloxacin otic?
If yes, continue to #7. If no, do not approve
7. Approve #1 bottle (7.5ml) for 7 days.
8. Is the request for prophylaxis following tympanostomy tube placement?
If yes, do not approve If no, do not approve.

If yes, continue to #10.

If no, do not approve.

10. Does the member have a history of compliance with asthma medications?

If yes, continue to #11.

If no, do not approve

11. Is the member currently on maintenance therapy with oral steroids (i.e., previous attempts at a steroid taper or dosage reduction lead to exacerbation)?

If yes, do not approve.

If no, continue to #12.

12. In the past year has the member had frequent asthma exacerbations resulting in repeated use of health care services, such as urgent care or ED visits or hospitalization?

If yes, approve for 12 weeks.

If no, do not approve.

Renewal Criteria:

1. Has the member had a reduction in asthma exacerbations necessitating frequent office visits, ED / urgent care visits, hospitalizations, oral steroids and demonstrated sustained clinical improvement from baseline while on Xolair?

If yes, approve for 6 months

If no, do not approve.

Oral Nutritional Supplements

Generic Name Lactose – Free Food, Lactose – Free Food/Fiber Nutritional Supplement

Brand Name Boost, Boost High Protein, Boost Plus, Ensure, Ensure Enlive, Ensure High Protein, Ensure Light, Ensure Plus, Ensure Plus HN, Jevity, Liquid Nutrition, Liquid Nutrition Plus, Nubasics, Nubasics Plus, Nutrition Plus, Osmolite, Pediasure, Pediasure with Fiber, Peptamen, Peptamen Junior, Promod, Resource, Resource Plus, Resource Diabetic

Revised: 6/7/10, 6/14/11, 5/21/12, 6/1/14, 03/10/16

Reviewed: 9/12/13

Age ≥ 6 years:

1. Is the nutritional supplement to be administered via enteral tube feeding (e.g. G-tube, NG-tube)?

If yes, close request If no, continue to #2.

2. Is the member currently on oral nutritional supplements?

If yes, continue to #3.

If no, continue to #4.

3. Has there been an annual assessment by the MD or RD for continued use and documentation indicates there is weight maintenance (no continued weight loss or low serum protein)?

If yes, approve for life.

If no, do not approve.

4. Does the member have a nutritional deficiency identified by any **ONE** of the following?

- Total protein < 5.6g/dl or albumin < 3.4g/dl **or**
- Registered Dietician assessment in the past 3 months indicates sufficient caloric/protein intake is not obtainable through regular, liquefied or pureed foods (i.e., liquefied/pureed foods have been tried and failed)

If yes, continue to #6

If no, continue to #5.

5. Does the member meet BOTH of the following criteria?

a. Prolonged history (years) of malnutrition and diagnosis or symptoms of cachexia and member resides in a home, nursing facility, or chronic home care facility.

b. Obtaining criteria from question #4 would be futile and invasive.

If yes, continue to #6.

If no, do not approve.

6. Does the member have an unplanned weight loss of ≥ 10%* **and ONE** of the following criteria?

- Severe trauma resulting in increased metabolic need (e.g., severe burn, major bone fracture), or
 - Malabsorption difficulty (e.g., Crohn's disease, short-gut syndrome, bowel resection, fistula, gastric bypass, cystic fibrosis, renal dialysis, dysphagia, achalasia), or
 - Diagnosis that requires additional calories (cancer, AIDS, Pulmonary insufficiency MS, ALS, Parkinson's, cerebral palsy, Alzheimer's)
- *Weight loss criteria may be waived if body weight is being maintained by supplements due to member's medical condition (e.g., renal failure, AIDS)
- If yes, approve for life. If no, do not approve.

Age < 6 years:

1. Is the nutritional supplement to be administered via enteral tube feeding (e.g. G-tube, NG-tube)?
If yes, close request If no, continue to #2.
2. Is the request for Infant formula or nutritional supplements available through WIC?
(note: WIC eligibility is for children less than age 5, proceed to #4 if 5 years old)
If yes, continue to #3. If no, continue to #4.
3. Is member unable to obtain formula type or quantity required through WIC program?
If yes, forward to RPh. If no, do not approve .
4. Is the member currently on oral nutritional supplements?
If yes, continue to #5. If no, continue to #6.
5. Has there been an annual assessment by the MD or RD for continued use and documentation indicates there is weight maintenance ?
If yes, approve x 12 mo. If no, do not approve.
6. Does the member have a diagnosis of failure to thrive?
If yes, continue to #7. If no, do not approve.
7. Does the member have a nutritional deficiency identified by any **ONE** of the following?
 - Total protein < 5.6g/dl or Albumin < 3.4g/dl, **or**
 - Registered dietician assessment in the past 3 months indicates sufficient caloric/protein intake is not attainable through regular, liquified or purified foods.
 If yes, approve x 12 months. If no, continue to #8.
8. Does the member meet **ONE** of the following criteria?

- Severe trauma resulting in increased metabolic need (e.g., severe burn, major bone fracture), or
- Malabsorption difficulty (e.g., Crohn's disease, short-gut syndrome, bowel resection, fistula, gastric bypass, cystic fibrosis, renal dialysis, dysphagia, achalasia), or
- Diagnosis that requires additional calories (cancer, AIDS, Pulmonary insufficiency MS, ALS, Parkinson's, cerebral palsy, Alzheimer's)

If yes, approve x 12 months.

If no, do not approve.

Generic Name: Oseltamivir

Brand Name: Tamiflu

Revised: 5/23/08, 11/29/11

Reviewed: 7/12/12, 9/12/13

Quantity Exception Criteria

1. Is the member older than 1 year of age?
If yes, then continue to #2. If no, then do not approve.
2. Is Tamiflu being used to treat influenza?
If yes, and the member has exceeded the annual quantity limit of 2 treatments/20 capsules) which does not require PA, review for clinical appropriateness. If no, continue to #3.
3. Is Tamiflu being used for influenza prophylaxis (prevention)?
If yes, continue to #4. If no, continue to #5
4. Has the member been exposed to the influenza virus (household or community outbreak)?
If yes, continue to #5. If no, do not approve.
5. Does the member have any of the following that places them at high risk for developing influenza complications?
 - a. ≥ 65 years of age
 - b. Pregnancy (category C)
 - c. Children meeting the age limit or teenagers who are receiving long-term aspirin treatment and may be at risk for developing Reye's syndrome.
 - d. Cardiovascular disease except hypertension
 - e. Chronic pulmonary disease (asthma or COPD)
 - f. Weakened immune system due to HIV/AIDS, immunosuppressive medications (e.g. transplant, steroids, TNFs), chemotherapy or radiation therapy
 - g. Renal disease
 - h. Hematological disorders (i.e. anemia)
 - i. Metabolic disease such as diabetes mellitus
 - j. Any muscle or nerve condition (e.g. spinal cord injuries, seizures, or cerebral palsy) or cognitive dysfunction that can lead to difficulty breathing or swallowing and increase the aspiration risk
 - k. Residents of nursing homes or other long-term care facilities
 - l. Currently resides with or cares for high-risk people (meeting one of the above criteria)If yes, continue to #6. If no, do not approve.

6. Approve with the following duration:
- 10 day therapy for household or community outbreaks.
 - 30 days for institutional outbreaks. If an extension needed then the provider needs to submit another prior authorization request.

Treatment

Body Weight	Recommended Dose for 5 days	Number of Bottles of the Oral Suspension (6mg/ml)	Number of Capsules (30mg, 45mg, 75mg)
≤ 15kg	30mg BID	1	10 of 30mg
16 to 23kg	45mg BID	2	10 of 45mg
24 to 40kg	60mg BID	2	20 of 30mg
> 40kg	75mg BID	3	10 of 75mg

Prophylaxis for Household Outbreaks

Body Weight	Recommended Dose for 10 days	Number of Bottles of the Oral Suspension (6mg/ml)	Number of Capsules (30mg, 45mg, 75mg)
≤ 15kg	30mg QD	1	10 of 30mg
16 to 23kg	45mg QD	2	10 of 45mg
24 to 40kg	60mg QD	2	20 of 30mg
> 40kg	75mg QD	3	10 of 75mg

Generic Name Oxandrolone

Brand Name Oxandrin

Revised: 11/21/08

Reviewed: 12/2/11, 9/13/12, 9/12/13

Revised: 01/14/16

Initial Criteria:

1. Does the member have a documented diagnosis of wasting syndrome (weight loss/cachexia) due to HIV/AIDS, cancer, severe COPD, chronic infection, extensive surgery, or trauma?
If yes, continue to #2. If no, continue to #4.
2. Has the member experienced a weight loss of $\geq 10\%$ in < 4 months and has a BMI < 20 ?
If yes, continue to #3. If no, do not approve.
3. Has the member tried/failed or have contraindications to megestrol?
If yes, continue to #7. If no, do not approve.
4. Is oxandrolone being used to offset protein breakdown (catabolism) that is associated with **chronic** corticosteroid use?
If yes, continue to #7. If no, continue to #5.
5. Does the member have a diagnosis of bone pain associated with osteoporosis?
If yes, continue to #6. If no, do not approve.
6. Has the member tried/failed or have contraindications to standard pain therapy including NSAIDs and opioids?
If yes, continue to #7. If no, do not approve.
7. Does the member have any of the following contraindications to use of oxandrolone?
 - Known or suspected carcinoma of the prostate or breast in males
 - Carcinoma of the breast in females with hypercalcemia
 - Hypercalcemia
 - NephrosisIf yes, do not approve. If no, continue to #8.
8. Wasting syndrome: Approve for 4 weeks.
All others: Approve for 12 months.

Renewal Criteria:

Cachexia/Wasting: Documentation of increase in or maintenance of (no continued loss) weight/BMI. Approve x 6 months.

Generic Name Palivizumab

Brand Name Synagis

Revised: 11/20/09, 9/16/10, 10/18/10, 01/10/11, 10/4/11, 10/21/11, 7/18/12, 10/9/12, 9/12/13, 08/19/14

The following are based off the American Academy of Pediatrics 2014 Synagis Guidelines:

1. Does the member meet **ANY** of the following?
 - a. Current age** < 12 months at the start of RSV season and gestational age <29 weeks, 0 days, **or**
 - b. Preterm infants who develop Chronic lung disease (CLD) of prematurity defined as birth at gestational age of <32 weeks, 0 days' gestation and a requirement for >21% oxygen for at least 28 days after birth **AND** one of the following:
 - i. Current age <12 months**; OR
 - ii. Current age 12-24 months** AND continued medical need for supplemental oxygen, chronic corticosteroids, or diuretic therapy during the 6 month period before the start of the RSV season
 - c. Current age < 12 months** with hemodynamically significant congenital heart disease (CHD) **and** at least one of the following:
 - i. acyanotic heart disease who are receiving medication to control CHF and will require cardiac surgical procedures **or**
 - ii. moderate to severe pulmonary hypertension, **or**
 - d. Current age ≤ 12 months** with congenital abnormalities of the airway or neuromuscular disease that impairs the ability to clear secretions from the upper airways. , **or**
 - e. Age less than 24 months** who will be profoundly immunocompromised during RSV season (such as chemotherapy, or post solid organ or stem cell transplant)

If yes, continue to #2. If no, deny.

** All referenced ages above are as of start of season.

2. Approve Synagis at a dose of 15mg/kg for up to a maximum of 5 total monthly doses until March 31 (projected end of RSV season). Qualifying infants born during RSV season may require fewer doses. If any infant or young child receiving monthly palivizumab prophylaxis experiences a breakthrough RSV hospitalization, monthly prophylaxis should be discontinued.

Generic Name: Pancrelipase
(Lipase-Amylase-Protease)

Brand Name: Creon
Pancreaze
Zenpep

Created: 03/09/17

1. Is the request for Viokace (non-formulary)?
If yes, continue to #2
If no, continue to #3.
2. Is the member taking a PPI? (omeprazole or pantoprazole)
If yes, continue to #3.
If no, do not approve.
3. Does the member have a diagnosis of cystic fibrosis?
If yes, continue to #9.
If no, continue to #4.
4. Has the member had a pancreatectomy?
If yes, continue to #9.
If no, continue to #5.
5. Does the member have a diagnosis of exocrine pancreatic cancer?
If yes, continue to #9.
If no, continue to #6.
6. Does the member have a diagnosis of chronic pancreatitis?
If yes, continue to #8.
If no, continue to #7.
7. Does the member have a diagnosis of malabsorption from a chronic condition?
(e.g. Crohn's Disease, celiac disease, bowel resection)
If yes, continue to #8.
If no, do not approve.
Deny for investigational.
8. Does the member have exocrine pancreatic insufficiency confirmed with one of the following methods?
 - Confirmed steatorrhea with fecal fat determination
 - Measurement of fecal elastase
 - Secretin pancreatic function testing
 - ImagingIf yes, continue to #9.
If no, do not approve.
9. Approve for lifetime.

Generic Name Paricalcitol
Brand Name Zemplar

Revised: 9/25/09

Reviewed: 12/2/11, 9/12/13

1. Does the member have Stage 3 (GFR 30-59), Stage 4 (GFR 15-29), or Stage 5 (GFR < 15 or dialysis) chronic kidney disease?

If yes, continue to #2.

If no, do not approve.

2. Does the member have iPTH values > 70 pg/mL if Stage 3, > 110 pg/mL if Stage 4, or > 300 pg/ml if Stage 5 on dialysis, corrected calcium levels < 9.5 mg/dL, and serum phosphorus levels < 4.6mg/dL?

If yes, continue to #3.

If no, do not approve.

3. Has the member tried and failed or have contraindications to Rocaltrol (calcitriol)?

If yes, continue to #4.

If no, do not approve

4. Approve x lifetime with quantity limit #12/month .

Generic Name: Patiromer

Brand Name: Veltassa

Created: 3/21/16

Initial:

1. Does the member have hyperkalemia based on potassium labs (vs reference ranges)?
If yes, continue to #2 If no, do not approve.

2. Has the member failed ALL of the following?

a) Dietary modifications; and

b) Dose modification (or discontinuation) of ACE-inhibitor, ARB, or other hyperkalemia causing agent; and

c) Diuretics

If yes, approve x 6 months.

If no, do not approve.

Renewal:

1. Has the member shown a meaningful response to therapy (such as returning to normal potassium levels or a significant drop from baseline)?

If yes, approve x 12 months.

If no, do not approve.

Generic Name Pegaptanib

Brand Name Macugen

Created: 3/13/12

Reviewed: 9/13/12, 9/12/13

*****Nonformulary for outpatient benefit. PA required on medical benefit.*****

1. Does the member have a diagnosis of Exudative (Wet) Age-Related Macular Degeneration (AMD) or Macular Edema following Retinal Vein Occlusion (RVO)?

If yes, continue to #2

If no, do not approve.

2. Has the member tried and failed Avastin?

If yes, approve for life.

If no, do not approve and recommend Avastin.

Generic Name Pegloticase

Brand Name Krystexxa

Created: 5/19/11

Reviewed: 7/12/12

Revised: 9/12/13

***** Nonformulary for outpatient benefit. PA required on medical benefit *****

Initial Criteria:

1. Is request for adult member with chronic gout with symptomatic hyperuricemia and one of the following:
 - a. Minimum 2 acute attacks in the past 12 months
 - b. At least 1 gout tophus
 - c. Gouty arthritisIf yes, continue to #2. If no, do not approve.
2. Is requested by a rheumatologist or nephrologist?
If yes, continue to #3. If no, do not approve.
3. Has member failed (defined as at least 2 acute attacks per year while on treatment) or have contraindication to all conventional therapies at maximum tolerable dose including:
 - a. allopurinol or probenecid
 - b. combination of allopurinol/Uloric and probenecid
 - c. Uloric
 - d. ColcrysIf yes, continue to #4. If no, do not approve and recommend untried medication(s)
4. Does member have glucose-6-phosphate dehydrogenase (G6PD) deficiency?
If yes, do not approve. If no, continue to #5
5. Approve x 3 months.

Renewal Criteria:

1. Has member achieved serum uric acid level of less than <6mg/dL?
If yes, approve x 6 months. If no, do not approve.

Generic Name Plerixafor

Brand Name Mozobil

Created: 10/16/15

Revised: 11/03/16, 01/12/17

*****Nonformulary on outpatient benefit. PA required for medical benefit.*****

Criteria:

1. Is the request for pre-transplant hematopoietic stem cell mobilization in non-Hodgkin lymphoma and multiple myeloma?
If yes, continue to #2. If no, do not approve.
2. Has the member had an unsuccessful mobilization with G-CSF (filgrastim) with or without cyclophosphamide?
If yes, continue to #5. If no, continue to #3.
3. Is the request for just-in-time or rescue treatment, requested before the mobilization to be used in the mobilization protocol if necessary?
If yes, continue to #4. If no, do not approve.
4. Has the provider documented a treatment protocol that specifies that Mozobil will only be used in case of mobilization failure in order to salvage the attempt in one of these clinical scenarios?
 - a. Peripheral blood CD34+ counts plateaued at $< 10 \times 10^9/L$ or declined without reaching a maximum of $10 \times 10^9/L$ after recovery of white blood cell counts following chemotherapy
 - b. The number of CD34+ cells collected was $< 0.3 \times 10^6$ per kilogram of body weight per day for 2 consecutive days
 - c. A progressive decline in daily collection yield.
If yes, continue to #5 If no, do not approve.
5. Will Mozobil be used in conjunction with filgrastim for four days prior to the first evening dose and each day prior to apheresis while using Mozobil?
If yes, approve for up to 4 doses over 4 days. If no, do not approve

Generic Name: Polidocanol

Brand Name: Varithena

Created: 09/22/14

*****Nonformulary on outpatient benefit. PA required for medical benefit.*****

1. Is the request for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee; improves symptoms of superficial venous incompetence and the appearance of visible varicosities.
If yes, continue to #2. If no, do not approve.
2. Is the condition causing or contributing to cellulitis or abscesses.
If yes, continue to #5. If no, continue to #3.
3. Is the member using for cosmetic purposes only?
If yes, deny for benefit exclusion. If no, continue to #4
4. Does the current prioritized list indicate this is a covered condition?
If yes, continue to #5. If no, deny for below the line.
5. Approve x 12 months.

2. Is the member unable to swallow capsules?

If yes, approve as above.

If no, do not approve.

Lyrice Renewal Criteria:

1. For treatment of DPN, postherpetic neuralgia, or spinal cord injury, did the prescriber submit documentation of improvement in pain or functioning since starting Lyrice?

If yes, approve for lifetime

If no, do not approve.

Generic Name Rabeprazole

Brand Name Aciphex

Created: 10/1/14

Revised: 12/26/14, 12/1/15

1. Is the member's age less than 19?

If yes, continue to #5

If no, continue to #2.

2. Is the diagnosis GERD?

If yes, continue to #3

If no, continue to #4

3. Does the request meet at least ONE of the following?:

a. Continuation of PPI therapy beyond 8 weeks (including other PPIs)?

OR

b. The request for more than 8 weeks or unspecified duration?

If yes, deny. Chronic GERD therapy
not covered per Guideline Note #144.

If no, continue to #5.

4. Does the member have a documented and medically appropriate diagnosis which is currently funded by the Oregon Health Plan (OHP) Prioritized List?

If yes, continue to #5.

If no, deny

5. Has the member tried and failed prescription omeprazole AND pantoprazole at twice daily dosing?

If yes, continue to #6.

If no, do not approve.

6. Approve with the following durations:

a. Kids: approve until age 19.

b. Adults with a covered diagnosis (not GERD): max 12 months

c. Adults with GERD: 8 weeks.

Generic Name Ranibizumab

Brand Name Lucentis

Created: 9/19/11

Revised: 3/13/12, 10/2/12, 05/14/15, 3/9/17, 6/7/17, 7/13/17

Reviewed: 9/12/13

*****Nonformulary for outpatient benefit. PA required on medical benefit.*****

1. Does the member have a diagnosis of:

- a. Exudative (Wet) Age-Related Macular Degeneration (AMD) or
- b. Macular Edema Following Retinal Vein Occlusion (RVO)?
- c. Diabetic Macular Edema with or without diabetic retinopathy?
- d. Myopic choroidal neovascularization (mCNV).
- e. Diabetic Retinopathy (DR)

If yes, continue to #2

If no, do not approve.

2. Has the member tried and failed Avastin?

If yes, approve for life.

If no, do not approve.

Generic Name: Reslizumab

Brand Name: Cinqair

Created: 7/19/16

*****Non-formulary on pharmacy benefit*****

Initial Criteria:

1. Is Cinqair being requested by a pulmonologist?
If yes, continue to #2. If no, do not approve.

2. Is the member ≥ 18 years?
If yes, continue to #3. If no, do not approve.

3. Does the member have a diagnosis of moderate to severe asthma with an eosinophilic phenotype?
If yes, continue to #4. If no, do not approve.

4. Is the member a current smoker?
If yes, do not approve. If no, continue to #5.

5. Is the member's recent eosinophil count of ≥ 400 cells/mcL?
If yes, continue to #6. If no, do not approve.

6. Has the member failed the following agents including as combination therapy:
 - a. High dose inhaled corticosteroid with a long acting beta agonist (such as Advair, Symbicort)
 - b. Long acting muscarinic antagonist (such as Spiriva)
 - c. Leukotriene inhibitor (such as montelukast)If yes, continue to #7. If no, do not approve.

7. Is the member currently on Xolair and intent is to continue Xolair while on Cinqair?
If yes, do not approve If no, continue to #8

8. Does the member have a history of compliance with asthma medications (above)?
If yes, approve x 6 months. If no, do not approve

Renewal Criteria:

1. Has the member had a reduction in asthma exacerbations necessitating frequent office visits, ED / urgent care visits, hospitalizations, oral steroids and demonstrated sustained clinical improvement from baseline while on Nucala?

If yes, approve for 6 months

If no, do not approve.

Generic Name Rifaximin

Brand Name Xifaxan

Created: 5/13/10

Reviewed: 7/12/12, 9/12/13

Revised: 7/11/13, 6/1/14, 07/27/15

1. Does the member have a diagnosis of hepatic encephalopathy associated with chronic liver disease?

 If yes, continue to #2.

 If no, do not approve.

2. Has the member failed a trial of lactulose?

 If yes, continue to #3.

 If no, do not approve .

3. Approve x life.

Generic Name: Riociguat

Brand Name: Adempas

Created: 1-14-14

1. Is Adempas being prescribed by a pulmonologist or cardiologist?
If yes, continue to #2. If no, do not approve.
2. Does the member have WHO class IV pulmonary arterial hypertension- chronic thromboembolic PAH?
If yes, continue to #3. If no, continue to #4.
3. Has the member failed surgical treatment or is not a surgical candidate?
If yes, continue to #6. If no, do not approve.
4. Does the member have class I PAH?
If yes, continue to #5. If no, do not approve.
5. Has the member failed or is a poor candidate for both of the following:
 - a. A PDE-5 inhibitor (e.g.- sildenafil or tadalafil) **AND**
 - b. An endothelin receptor antagonist (e.g.- ambrisentan, bosentan, or macitentan)If yes, continue to #6. If no, do not approve.
6. Approve for 6 months.

Renewal Criteria:

1. Has the member had documented response to treatment?
If yes, approve x 12 months. If no, do not approve.

1. Has there been a resolution or improvement in disease-related signs and symptoms or has the member achieved remission?
If yes, approve x 12 months. If no, do not approve.

Renewal Criteria

ITP:

1. Has the member since relapsed with a platelet count less than 20,000/microliter?
If yes, approve for 2 doses. If no, do not approve.

Renewal Criteria

MS:

1. Is the CD 19 count undetectable 1-4 weeks prior to the next dose (6 months after initial dose)?
If yes, approve 500mg every 6 months for 12 months If no, approve 1,000mg x 1 (next dose due in 6 months)

Renewal Criteria

NMO:

1. Has the provider documented a reduction in relapse rate since initiation of rituximab therapy?
If yes, approve 1,000 mg Q 6 months x 12 months. If no, deny

Generic Name Romiplostim
Brand Name Nplate

Created: 01/04/11

Reviewed: 7/12/12, 9/12/13

***** Non-formulary for outpatient benefit. PA required for medical benefit *****

Initial criteria:

1. Does the member have a diagnosis of chronic immune (idiopathic) thrombocytopenic purpura (ITP) at risk for bleeding?
If yes, continue to #2. If no, do not approve.
2. Is Nplate being prescribed by a hematologist?
If yes, continue to #3. If no, do not approve.
3. Is the member at least 18 years of age?
If yes, continue to #4. If no, do not approve.
4. Is there medical record documentation of platelet count of less than 20,000 per mm³ or less than 30,000 per mm³ with symptoms of bleeding?
If yes, continue to #5. If no, do not approve.
5. Is there documentation of failure of or contraindication to ALL of the following:
 - a. Systemic corticosteroids
 - b. Immunoglobulin replacement
 - c. Splenectomy

If yes, approve x 4 weeks.
Approved dosing: 1mcg/kg SC q week
adjusted weekly by 1 mcg/kg, maximum
weekly dose is 10 mcg/kg.

If no, do not approve and
recommend untried alternatives
listed above.

Renewal criteria:

1. Is there medical record documentation of maintenance of platelet counts \geq 50,000 per mm³ or an increase in platelet counts from baseline with resolution of bleeding episodes?
If yes, approve x 6 months. If no, do not approve.

Generic Name: Secukinumab

Brand Name: Cosentyx

Created: 07/09/15

Revised: 5/12/16, 01/12/17

Plaque Psoriasis:

Initial Criteria:

1. Does the member have active, chronic, moderate to severe Plaque Psoriasis at baseline meeting both criteria of Guideline Note 21:
 - a. Causing functional impairment (inability to use hands or feet or significant facial involvement preventing normal social interaction)
 - b. Affecting $\geq 10\%$ of the body and/or hand, foot, mucous membrane involvementIf yes, continue to #2. If no, do not approve.
2. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #3.
3. Has the treatment been prescribed or is it currently being supervised by a dermatologist?
If yes, continue to #4. If no, do not approve.
4. Has the member tried and failed or have contraindications to Humira AND Remicade?
If yes, continue to #5. If no, do not approve.
5. Approve for 6 months for 300 mg per dose induction and 300 mg Q4 week maintenance

Renewal criteria:

1. Has the member experienced a 50% improvement in affected body surface area, plaque severity and/or functioning?
If yes, approve for 12 months If no, do not approve.

Psoriatic arthritis:

Initial:

1. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #2.
2. Has the treatment been initiated by or is a rheumatologist or dermatologist currently supervising it?
If yes, continue to #3. If no, do not approve.
3. Does the member have psoriatic arthritis based on at least 3 out of 5 of the following?

- Psoriasis (1 point for personal or family history, 2 points for current)
- Psoriatic nail dystrophy
- Negative rest result for RF
- Dactylitis (current or history)
- Radiological evidence of juxta-articular new bone formation

If yes, continue to #4.

If no, do not approve.

4. Has the member failed or have contraindications to conventional management with **all** of the following?

- NSAIDs, and
- Methotrexate (or other DMARD such as leflunomide or sulfasalazine), and
- Both of the following: Humira **and** Enbrel

If yes, continue to #5.

If no, do not approve.

5. Approve for 6 months for 150 mg per dose induction and 150 mg Q4 week maintenance

Renewal:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count?

If yes, continue to #2.

If no, do not approve.

2. Approve for 12 months. Approved dosing: 150mg every 4 weeks

Ankylosing Spondilitis

Initial Criteria:

1. Does the member have an active infection or a history of recurring infections?

If yes, do not approve.

If no, continue to #2.

2. Has the treatment been initiated by or is a rheumatologist currently supervising it?

If yes, continue to #3.

If no, do not approve.

3. Does the member have ankylosing spondylitis? Diagnosis is definitive if both are met:

a. Radiological evidence of sacroilitis

b. Clinical evidence with two of three:

i. low back pain and stiffness for more than 3 months which improves with exercise but is not relieved by rest;

ii. limitation of motion of the lumbar spine in the sagittal and frontal planes;

iii. limitation of chest expansion relative to normal values correlated for age and sex

If yes, continue to #4.

If no, do not approve.

4. Does the member have moderate to severe active disease, evidenced by a Bath AS Disease Activity Index (BASDAI) score of at least 4?

If yes, continue to #5.

If no, do not approve.

5. Has the member tried and failed conventional therapy with **all** of the following:

- At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, and
- Physical therapy/exercise program, and
- For axial disease only: Sulfasalazine for at least 4 months at standard target dose or maximally tolerated dose.

If yes, continue to #6.

If no, do not approve.

6. Approve for 6 months for 150 mg per dose induction and 150 mg Q4 week maintenance

Renewal Criteria:

Ankylosing Spondylitis:

1. Does the member have significant improvement in signs and symptoms of AS and/or functioning, such as 50% relative change or 2-point improvement in BASDAI?

If yes, approve for 12 months.

If no, do not approve

Approved dosing: 150mg every 4 weeks

Renewal Criteria:

1. Does the member meet any of the following treatment goals?
 - a. A significant increase in the 6 minute walk test
 - b. Decrease in dyspnea fatigue rating and other symptoms
 - c. Evidence of hemodynamic improvement such as a reduction in mPAP and PVR
 - d. Improvement in NYHA functional class
 - e. Lack of functional or hemodynamic deterioration

If yes, approve x 12 months.

If no, do not approve.

Generic Name Pegvisomant

Brand Name Somavert

Created: 03-05-14

Revised: 03/09/17

Initial Criteria:

1. Does the member have a diagnosis of acromegaly confirmed by elevated IGF-1 levels?
If yes, continue to #2. If no, do not approve.
2. Is the acromegaly moderate to severe or symptomatic?
If yes, continue to #3. If no, do not approve.
3. Does the member have persistent disease after surgery or considered not to be a candidate for surgery?
If yes, continue to #4. If no, do not approve.
4. Is the request for combination therapy with a somatostatin receptor ligand, such as octreotide, lanreotide, or pasireotide?
If yes, continue to #6. If no, continue to #5.
5. Has the member tried and failed or have a contraindication to a somatostatin receptor ligand, such as octreotide, lanreotide, or pasireotide?
If yes, approve for 6 months. If no, do not approve.
6. Has the member failed or have contraindications to combination therapy with a somatostatin receptor ligand and a dopamine agonist, such as cabergoline or bromocriptine?
If yes, approve for 6 months. If no, do not approve.

Renewal Criteria:

1. Has the member had a reduction in or reached a target goal of an age-normalized serum IGF-1 value?
If yes, approve for 6 months. If no, do not approve.

Generic Name Sacubitril/valsartan

Brand Name Entresto

Created: 11/23/15

5. Is the request for the treatment of NYHA Class II to IV chronic heart failure?
If yes, continue to #2. If no, deny.
6. Does the member have an ejection fraction $\leq 40\%$?
If yes, continue #3. If no, deny.
7. Is the request from a cardiologist?
If yes, continue to #4. If no, deny.
 - a. Is the member on maximum tolerated doses of ALL of the following classes? Beta-Blocker [metoprolol succinate (200mg/day), carvedilol (25mg twice daily)] bisoprolol NF (10mg/day)
 - b. ACE-i/ARB [captopril (50mg three times daily), enalapril (10mg twice daily), lisinopril (20mg/day), ramipril (5mg twice daily), losartan (150mg/day)], perindopril (8mg/day), trandopril (4mg/day), valsartan (160mg twice daily), candesartan (32mg/day)
Mineralcorticoid receptor antagonist [spironolactone (25 mg/day)]
eplerenone (50 mg/day)

If yes, continue to #5. If no, deny.
5. Is the plan clear to discontinue existing ACEi or ARB therapy before beginning Entresto (contraindicated to be on both)?
If yes, approve x life. If no, contact provider to verify plan intent.

Generic Name: Sebelipase alfa

Brand Name: Kanuma

Created: 3/21/16

*****Non-formulary for pharmacy benefit*****

Initial:

1. Is the diagnosis lysosomal acid lipase (LAL) confirmed by genetic testing?
If yes, continue to #2. If no, deny.
2. Is the request from an appropriate specialist such as hepatologist?
If yes, continue to #3. If no, deny.
3. Is there documented liver involvement/disease such as elevated LFTs (ALT/AST 3x above normal limit) and poorly controlled lipids?
If yes, approve x 20 weeks. If no, deny.

Renewal:

1. Has there been a documented response to therapy such as normalization or improvement in liver enzyme function tests (LFTs)?
If yes, approve x 12 months. If no, deny.

Generic Name Sofosbuvir,
Ledipasvir/Sofosbuvir,
Daclatasvir,
Elbasvir/grazoprevir,
Sofosbuvir/Velpatasvir,
Ribavirin

Brand Name Sovaldi, Harvoni, Daklinza, Zepatier, Epclusa, Ribavirin

Created: 07/11/14

Updated: 11/5/14, 5/13/15, 11/23/15, 3/9/16, 7/18/16, 9/8/16, 1/1/17, 6/1/17

Criteria shall apply to all Hepatitis C treatment regimens including non-formulary requests. Any non-formulary request should also be scrutinized for not using our preferred options which are in the table below.

New Starts Only:

1. Is expected survival from non-HCV-associated morbidities more than 1 year?
If yes, continue to #2. If no, do not approve.

2. Has ALL of the following pre-treatment testing been documented and submitted?
 - a. Genotype testing (within 3 years)
 - b. Baseline HCV RNA in past 6 months (must be quantifiable, not just detected)
 - c. HIV status
 - d. HBV status (Treatment can re-activate HepB)
 - e. Pregnancy test (past 30 days) for a woman of child-bearing age
 - f. History of previous HCV treatment and outcomeIf yes, continue to #3. If no, do not approve.

3. Has the member failed treatment any of the following HCV NS5A inhibitors?:
 - a. Daklinza and Sovaldi
 - b. Harvoni
 - c. Viekira
 - d. Zepatier
 - e. EpclusaIf yes, review for medical urgency with Medical Director (and benefit lead) If no, continue to #4

4. Does the member have HIV and Stage 2 fibrosis verified by one of the following
 - a. Biopsy
 - b. Elastography: Fibroscan or Shear-Wave

If yes, continue to #8.

If no, deny.

8. Is the treatment prescribed by a specialist or in consultation with (or program trained by) a specialist in hepatology, gastroenterology or infectious disease?

If yes, continue to #9

If no, deny

9. In the previous 6 months:

a. Has the patient actively abused alcohol (>14 drinks per week for men or >7 drinks per week for women or binge alcohol use [>4 drinks per occasion at least once a month]); **OR**

b. Has the patient been diagnosed with a substance use disorder; **OR**

c. Is the prescriber aware of current alcohol abuse or illicit injectable drug use?

If yes, continue to #10

If no, continue to #11

10. Is the patient enrolled in a treatment program under the care of an addiction/substance use treatment specialist?

If yes, continue to #11

If no, deny.

11. Will the patient and provider comply with all case management interventions and adhere to monitoring requirements required by the Oregon Health Authority, including measuring and reporting of a post-treatment viral load?

If yes, continue to #12

If no, deny

12. Is the prescribed drug for Zepatier for genotype 1a or Daklinza/Sovaldi for genotype 3 infection?

If yes, continue to #13

If no, continue to #14

13. Has the patient had a baseline NS5a resistance test show a resistant variant to one of the agents?

If yes, deny and recommend alternative egimen.

If no, continue to #14

14. Does the request match one of the regimens below?

If yes, approve for duration noted.

If no, deny criteria not met and cite alternative required.

and cite alternative required.

Approved Regimens (continued next page)

Genotype	Cirrhosis Status	Recommended Regimen
Genotype 1		
Treatment Naïve	Non-cirrhotic	Zepatier x 12 weeks; OR Harvoni x 12 weeks
	Compensated Cirrhosis	Zepatier x 12 weeks; OR Harvoni x 12 weeks
	Decompensated Cirrhosis	Harvoni+RBV x 12 weeks
Treatment-Experienced	Non-cirrhotic	Zepatier x 12 weeks; OR Harvoni +/-RBV x 12 weeks
	Compensated Cirrhosis	Zepatier x 12 weeks; OR Harvoni + RBV x 12 weeks
	Decompensated Cirrhosis	Harvoni x 24 weeks
Genotype 2		
Naïve or Experienced	Non-cirrhotic	Epclusa x 12 weeks
	Compensated Cirrhosis	Epclusa + RBV x 12 weeks
	Decompensated Cirrhosis	Epclusa + RBV x 12 weeks
Genotype 3		
Naïve or Experienced	Non-cirrhotic	Harvoni + RBV x 12 weeks OR Epclusa x 12 weeks
	Compensated Cirrhosis	Epclusa + RBV x 12 weeks
	Decompensated Cirrhosis	Epclusa + RBV x 12 weeks
Genotype 4		
Naïve or Experienced	Non-cirrhotic	Zepatier x 12 weeks; OR Harvoni x 12 weeks
	Compensated Cirrhosis	Zepatier x 12 weeks; OR Harvoni x 12 weeks
	Decompensated Cirrhosis	Harvoni+RBV x 12 weeks
Genotypes 5 and 6		
Naïve or Experienced	With or without compensated cirrhosis	Harvoni x 12 weeks

Generic Name Teriparatide
Abaloparatide

Brand Name Forteo
Tymlos

***** Nonformulary on the outpatient benefit. PA required for medical benefit *****

Revised: 11/20/09

Reviewed: 12/2/11, 9/13/12, 9/12/13

1. Does the member have any of the following exclusionary criteria that places him/her at increased baseline risk for osteosarcoma: Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, or prior external beam or implant radiation therapy involving the skeleton)?

If yes, do not approve.

If no, continue to #2.

2. Is the member a post-menopausal female with ONE of the following:

- Radiographic evidence of an osteoporotic fracture while compliant on a bisphosphonate for ≥ 12 months High risk of fracture AND a) documented adverse event with a bisphosphonate despite proper administration or b) contraindication to bisphosphonate.

If yes, continue to #5.

If no, continue to #3.

1. Is the member a male or female with steroid-induced osteoporosis and ALL of the following:

- a. Steroid use for > 3 months at a dose of 5mg/d prednisone (or equivalent), and
- b. BMD T-score < -2.5 , and
- c. ONE of the following:

1. Radiographic evidence of an osteoporotic fracture while compliant on a bisphosphonate¹ for ≥ 12 months (check refill history, member should have at least 6 consecutive month fills)
2. Documented adverse event with a bisphosphonate¹ despite proper administration or contraindication³ to bisphosphonate¹.

If yes, continue to #5.

If no, continue to #4.

2. Is the member a male with a diagnosis of primary or hypogonadal osteoporosis and ALL of the following:

- a. History of osteoporotic fracture with radiographic evidence
- b. Multiple fracture risk factors²
- c. Compliant on bisphosphonate¹ for ≥ 12 months (check refill history, member should have at least 6 consecutive month fills) or history of a serious adverse event despite proper administration or contraindication to bisphosphonate¹ therapy.

If yes, continue to #5.

If no, do not approve.

5. Approve for 2 years.

Generic Name Tigecycline

Brand Name Tygacil

Created: 5/27/09

Reviewed: 7/12/12, 9/12/13

1. Is the member being treated by an Infectious Disease Specialist?
If yes, continue to #2 If no, do not approve.
2. Is the member \geq 18 years old?
If yes, continue to #3 If no, do not approve.
3. Does the member have a diagnosis of complicated skin and skin structure infections (CSSIs), complicated intra-abdominal infections (CIABs), or community acquired pneumonia (CAP) that is resistant to standard therapies?
 1. CSSIs: vancomycin, beta lactam
 2. CIABs: imipenim/cilastim
 3. CAP: severe infection requiring IV therapy and resistant to a beta-lactam, such as cefotaxime, ceftriaxone plus azithromycin or Zosyn and a fluoroquinolone such as levofloxacin or moxifloxacin

If yes, approve the duration requested.

If no, do not approve.

7. Is the request for induction of remission?
If yes, continue to #8. If no, continue to #9.
8. Has the member failed to achieve remission with prednisone or methylprednisolone?
If yes, continue to #11. If no, do not approve.
9. Is the member currently stable on steroids and considered steroid-dependent?
If yes, continue to #10. If no, do not approve.
10. Has the member tried azathioprine, 6-mercaptopurine, or methotrexate for maintenance?
If yes, continue to #11. If no, do not approve.
11. Is the requested product indicated for or supported for use in Crohn's Disease?
If yes, continue to #12. If no, do not approve.
12. Approve for 6 months.

Renewal Criteria:

Crohn's Disease

1. Has the member experienced a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission?
If yes, approve for 12 months. If no, do not approve.

Ulcerative Colitis

Initial Criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?
If yes, continue to renewal criteria. If no, continue to #2.
2. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #3.
3. Is the request being initiated by or supervised by a gastroenterologist?
If yes, continue to #4. If no, do not approve.
4. Does the member have a diagnosis of moderate to severe ulcerative colitis defined by the following criteria:
 - Moderate = greater than or equal to 4 stools daily.
 - Severe = greater than or equal to 6 bloody stools daily and evidence of toxicity such as fever, anemia, elevated ESR, or tachycardia.

If yes, continue to #5.

If no, do not approve.

5. Is the member transitioning to the requested treatment from a different biologic product?

If yes, continue to #10

If no, continue to #6.

6. Is the request for induction of remission?

If yes, continue to #7.

If no, continue to #8.

7. Has the member failed to achieve remission with prednisone or methylprednisolone?

If yes, continue to #10.

If no, do not approve.

8. Is the member currently stable on steroids and considered steroid-dependent?

If yes, continue to #9.

If no, do not approve.

9. Has the member tried azathioprine, 6-mercaptopurine, mesalamine, or sulfasalazine for maintenance?

If yes, continue to #10.

If no, do not approve.

10. Is the requested product indicated for or supported for use in ulcerative colitis?

If yes, continue to #11.

If no, do not approve.

11. Approve for 6 months.

Renewal Criteria:

Ulcerative colitis

1. Has the member demonstrated a significant response including the following:

- Decrease in bloody stools per day and/or
- Elimination of signs of toxicity

If yes, approve for 12 months.

If no, do not approve.

Rheumatoid Arthritis

Initial Criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?

If yes, continue to renewal criteria.

If no, continue to #2.

2. Does the member have an active infection or a history of recurring infections?

If yes, do not approve.

If no, continue to #3.

3. Has the treatment been initiated by or is a rheumatologist currently supervising it?

If yes, continue to #4.

If no, do not approve.

4. Does the member have a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)?
If yes, continue to #5. If no, do not approve.
5. Is the member transitioning to the requested treatment from a different biologic product?
If yes, continue to #8 If no, continue to #6.
6. Has the member tried and failed or have contraindications to methotrexate dosed at least 20mg per week for at least 8 weeks?
If yes, continue to #7. If no, do not approve.
7. Has the member tried and failed or have contraindications to the following: leflunomide, hydroxychloroquine, or sulfasalazine?
If yes, continue to #8. If no, do not approve.
8. Is the requested product being prescribed along with at least one of the following DMARDs: methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine, unless contraindicated?
If yes, continue to #9. If no, do not approve.
9. Approve for 6 months.

Renewal Criteria:

Rheumatoid Arthritis:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count?
If yes, approve for 12 months. If no, do not approve.

Psoriatic Arthritis

Initial Criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?
If yes, continue to renewal criteria. If no, continue to #2.
2. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #3.
3. Has the treatment been initiated by or is a rheumatologist or dermatologist currently supervising it?
If yes, continue to #4. If no, do not approve.
4. Does the member have psoriatic arthritis based on at least 3 out of 5 of the following?

- Psoriasis (1 point for personal or family history, 2 points for current)
- Psoriatic nail dystrophy
- Negative test result for RF
- Dactylitis (current or history)
- Radiological evidence of juxta-articular new bone formation
If yes, continue to #5 If no, do not approve.

5. Is the member transitioning to the requested treatment from a different biologic product?

If yes, continue to #7.

If no, continue to #6.

6. Has the member failed or have contraindications to conventional management with all of the following?

- NSAIDs, and
- Methotrexate or other DMARD such as leflunomide or sulfasalazine.
If yes, continue to #7. If no, do not approve

7. Approve for 6 months.

Renewal Criteria:

Psoriatic Arthritis:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count?

If yes, continue to #2.

If no, do not approve.

2. Approve for 12 months.

Ankylosing Spondylitis

Initial Criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?

If yes, continue to renewal criteria.

If no, continue to #2.

2. Does the member have an active infection or a history of recurring infections?

If yes, do not approve.

If no, continue to #3.

3. Has the treatment been initiated by or is a rheumatologist currently supervising it?

If yes, continue to #4.

If no, do not approve.

4. Does the member have ankylosing spondylitis? Diagnosis is definitive if both are met:

- a. Radiological evidence of sacroilitis
- b. Clinical evidence with two of three:

- i. low back pain and stiffness for more than 3 months which improves with exercise but is not relieved by rest;
 - ii. limitation of motion of the lumbar spine in the sagittal and frontal planes;
 - iii. limitation of chest expansion relative to normal values correlated for age and sex
- If yes, continue to #5 If no, do not approve.

5. Is the member transitioning to the requested treatment from a different biologic product?

If yes, continue to #8. If no, continue to #6.

6. Does the member have moderate to severe active disease, evidenced by a Bath AS Disease Activity Index (BASDAI) score of at least 4?

If yes, continue to #7. If no, do not approve.

7. Has the member tried and failed conventional therapy with **all** of the following:

- At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, **and**
- Physical therapy/exercise program, **and**
- For axial disease only: Sulfasalazine for at least 4 months at standard target dose or maximally tolerated dose.

If yes, continue to #8. If no, do not approve.

8. Approve for 6 months.

Renewal Criteria:

Ankylosing Spondylitis:

1. Does the member have significant improvement in signs and symptoms of AS and/or functioning, such as 50% relative change or 2-point improvement in BASDAI ?

If yes, approve for 12 months. If no, do not approve.

Juvenile Idiopathic Arthritis (JIA)

Initial Criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?

If yes, continue to renewal criteria. If no, continue to #2.

2. Is the member 2 years or older?

If yes, continue to #3. If no, do not approve.

3. Does the member have an active infection or a history of recurring infections?

If yes, do not approve. If no, continue to #4.

4. Has the treatment been prescribed or is a rheumatologist currently supervising it?
If yes, continue to #5. If no, do not approve.
5. Does the member have moderately to severely active juvenile idiopathic arthritis?
If yes, continue to #6. If no, do not approve.
6. Is the member transitioning to the requested treatment from a different biologic product?
If yes, continue to #9. If no, continue to #7.
7. Has the member had a trial of glucocorticoid injections if fewer than 4 joints affected?
If yes, continue to #8. If no, do not approve.
8. Has the member tried and failed or have contraindications to methotrexate for at least 3 months?
If yes, continue to #9. If no, do not approve.
9. Is the requested product indicated for or supported for use in juvenile idiopathic arthritis?
a. If yes, continue to #10 If no, do not approve.
10. Approve for 6 months.

Renewal Criteria:

Juvenile Idiopathic Arthritis:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability?
If yes, approve for 12 months. If no, do not approve.

Plaque Psoriasis

Initial Criteria:

1. Does the member have chronic, moderate to severe plaque psoriasis at baseline with functional impairment and one or more of the following:
 - a. At least 10% body surface area involved
 - b. Hand, foot or mucous membrane involvement

If yes, continue to #2 If no, do not approve.
 Plaque psoriasis without functional impairment and hand, foot or mucus membrane involvement or affecting < 10% of body surface area is not covered for treatment by the Oregon Health Plan.

2. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?
If yes, continue to renewal criteria. If no, continue to #3.
3. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #4.
4. Has the treatment been prescribed or is it currently being supervised by a dermatologist?
If yes, continue to #5. If no, do not approve.
5. Is the member transitioning to the requested treatment from a different biologic product?
If yes, continue to #7. If no, continue to #6.
6. Has the member tried and failed or have contraindications to ALL of the following:
 - High-potency topical corticosteroids (betamethasone dipropionate, clobetasol, fluocinonide), **and**
 - At least one other topical agent: calcipotriol, tazarotene, anthralin, tar, and
 - PUVA or UVB Phototherapy, **and**
 - Methotrexate, **and**
 - At least one other second line systemic agent such as cyclosporine or acitretin.
 If yes, continue to #7. If no, do not approve.
7. Approve for 6 months.

Renewal Criteria:

Plaque Psoriasis:

1. Has the member experienced a 50% reduction in plaques and/or is there evidence of functional improvement?
If yes, approve for 12 months. If no, do not approve.

Non-infections Uveitis:

Initial criteria:

1. Is the request for maintenance of remission in a patient who already achieved remission with of the requested product or has already initiated therapy?
If yes, continue to renewal criteria. If no, continue to #2.
2. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #3.
3. Is the request from an appropriate specialist such as ophthalmology or rheumatology?
If yes, continue to #4. If no, do not approve.

4. Does the member have a diagnosis of non-infectious, intermediate, posterior or panuveitis?
If yes, continue to #5. If no, do not approve.
5. Is the member transitioning to the requested treatment from a different biologic product?
If yes, continue to #7. If no, continue to #6.
6. Has the member failed one of each of the following?
 - Topical glucocorticoids (prednisolone acetate, fluprednate) for at least 1 month, **and**
 - Oral corticosteroids, **and**
 - MethotrexateIf yes, continue to #6 If no, do not approve
7. Is the requested product supported for uveitis?
If yes, continue to #8. If no, do not approve.
8. Approve for 6 months.

Renewal criteria:

1. Is there documentation that disease activity has been controlled, such as a lack of inflammation, no new inflammatory vascular lesions, no vitreous haze or decreases in visual acuity?
If yes, approve for 12 months. If no, do not approve.

Quantity Exception Criteria on all indications:

Quantity limit exception criteria may be used if the standard criteria are met.

Enbrel:

1. Member has plaque psoriasis. May approve up to eight 50 mg syringes/autoinjectors for a 28-day supply.
2. Member has RA, JIA, PsA, or ankylosing spondylitis and is started and stabilized on 50 mg twice weekly dosing. May approve up to eight 50 mg syringes/autoinjectors for a 28-day supply.
3. Member has RA and the dose of Enbrel is being increased to 50 mg twice weekly. May approve up to eight 50 mg syringes for a 28-day supply if the member has taken methotrexate (MTX) in combination with Enbrel 50 mg once weekly or 25 mg twice weekly for at least 2 months.
4. Member has RA and the dose of Enbrel is being increased to 50 mg twice weekly. May approve up to eight 50 mg syringes for a 28-day supply if the member is currently receiving Enbrel 50 mg once weekly or 25 mg twice weekly and is either unable to tolerate MTX or MTX is contraindicated.
5. Member has JIA, PsA, or ankylosing spondylitis and the dose of Enbrel is being increased to 50 mg twice weekly or 25 mg twice weekly. May approve up to eight

50 mg syringes for a 28-day supply if the member has taken Enbrel dosed 50 mg once weekly for at least 2 months.

6. Overrides for other indications are not recommended.

Humira:

1. Member has uveitis. The loading dose is 80mg, approve 4 syringes for a 34 day supply the first month fill.
2. Member has RA, PsA, ankylosing spondylitis, Crohn's Disease or plaque psoriasis and is started and stabilized on 40 mg once weekly dosing: approve up to 4 syringes for a 28-day supply.
3. Member has plaque psoriasis and induction therapy is being initiated (consisting of 80 mg once followed in one week by 40 mg every other week), recommend the Psoriasis Starter Pack.
4. Member has Crohn's Disease and induction therapy with Humira is being initiated (consisting of 160 mg at week 0 followed by 80 mg at week 2, then 40 mg every other week beginning at week 4), recommend the Crohn's Starter Pack.
5. Member has Crohn's Disease and the dose of Humira is being increased to 40 mg once weekly or 80 mg every other week. Approve up to 4 syringes for a 28-day supply if the member has been taking Humira dosed 40 mg every other week for at least 4 weeks.
6. Member has RA and the dose of Humira is being increased to 40 mg once weekly. Approve up to 4 syringes for a 28-day supply if the member has taken MTX (or other DMARD if MTX is contraindicated) in combination with Humira dosed 40 mg every other week for at least 2 months.
7. Member has RA and the dose of Humira is being increased to 40 mg once weekly. Approve up to 4 syringes for a 28-day supply if the member is currently receiving Humira dosed 40 mg every other week and is either unable to tolerate MTX (or any DMARD) or MTX (or all other DMARDS) are contraindicated.
8. Member has PsA, ankylosing spondylitis, or plaque psoriasis and the dose of Humira is being increased to 40 mg once weekly. Approve up to 4 syringes for a 28-day supply if the member has taken Humira dosed 40 mg every other week for at least 2 months.
9. A quantity override for other indications is not recommended. No information is currently available on using once weekly dosing in JIA.

Remicade:

1. Member has Crohn's Disease or RA and is started and stabilized on an escalated dose or shortened interval, approve appropriate number of units.
2. Member has Crohn's Disease and the dose is being increased up to 10mg/kg or the dosage interval is being shortened. Approve if member has been properly induced and has been on therapy for at least 3 months.
3. Member has RA and the dose is being increased up to 10mg/kg or the dosage interval is being shortened. Approve if member has been properly induced and has been on MTX in combination with Remicade for at least 3 months.
4. Member has RA and the dose is being increased up to 10mg/kg or the dosage interval is being shortened. Approve if member has been properly induced and

has been on Remicade for at least 3 months and is either unable to tolerate MTX or MTX is contraindicated.

5. A quantity override for other indications is not recommended.

Generic Name Umeclidinium/Vilanterol
 Tiotropium/Olodaterol

Brand Name Anoro Elipta
 Stiolto Respimat

Revised: 9/4/08, 9/20/11, 9/12/13, 7/22/14, 1/2/15, 8/31/15

Reviewed: 5/10/12

1. Does the member have a diagnosis of COPD or emphysema?

 If yes, approve x life.

 If no, do not approve.

Initial Criteria

Systemic Juvenile Idiopathic Arthritis:

1. Is the member's current age \geq 2 years?
If yes, continue to #2. If no, do not approve.

2. Is the request from a rheumatologist?
If yes, continue to #3. If no, do not approve.

3. Does the member have a diagnosis of systemic juvenile idiopathic arthritis?
If yes, continue to #4. If no, do not approve.

4. Has the member tried and failed or have contraindications to methotrexate?
If yes, continue to #5. If no, do not approve.

5. Does the member have medical record documentation of all of the following:
 - a. absolute neutrophil count (ANC) above 2000/mm³, and
 - b. platelet count above 100,000/mm³, and
 - c. ALT or AST below 1.5 times the upper limit of normal (ULN)If yes, continue to #6. If no, do not approve.

6. Approve for 6 months.

Renewal Criteria:

Systemic Juvenile Idiopathic Arthritis:

1. Is there medical record documentation of disease stability or improvement in any of the following: tender joint count or swollen joint count, function, pain or ability to perform ADLs?
If yes, continue to #2. If no, do not approve.

2. Is there medical record documentation of laboratory monitoring of neutrophils, platelets, LFTs, and lipids?
If yes, approve x 12 months. If no, do not approve.

The combined use of Actemra and another biologic DMARD including Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Orenica (abatacept), Kineret (anakinra), Cimizia (certolizumab pegol) and Rituxan (rituximab) is considered investigational and will not be authorized.

Generic Name Tolterodine

Brand Name Detrol

Created: 9/26/12

1. Does the member have a diagnosis of overactive bladder that is covered by the Prioritized List?

If yes, continue to #2.

If no, do not approve.

2. Has the member failed a trial of oxybutynin?

If yes, approve x life.

If no, do not approve.

Generic Name Tranexamic acid

Brand Name Lysteda

Created: 01/03/17

Initial Criteria

1. Does the member have a bleeding disorder and the request is to prevent bleeding in a dental procedure?
 If yes, approve for 1 month. If no, continue to #2.

2. Does the member have a diagnosis of menorrhagia or abnormal uterine bleeding?
 If yes, continue to #3. If no, do not approve.

3. Does the member have an underlying bleeding disorder such as von Willebrand's or hemophilia?
 If yes, approve for 12 months If no, continue to #4.

4. Is the diagnosis characterized by all of the following:
 - Profuse bleeding lasting more than 7 days or repetitive periods at less than 21-day intervals.
 - Anemia due to acute or chronic blood loss (hemoglobin less than 10 g/dL or hemoglobin less than 11 g/dL if use of iron is documented).
 - Bleeding causes major impairment or interferes with quality of life. If yes, continue to #5 If no, do not approve.

5. Has the member failed a 6 month trial of combination oral contraceptives, or if estrogens are contraindicated, a progestin such as medroxyprogesterone or progestin oral contraceptive?
 If yes, continue to #6. If no, do not approve.

6. Has the member failed a trial of naproxen given on a scheduled basis at maximum tolerated dose starting the first day of menses for 5 days or until menses cease?
 If yes, continue to #7 If no, do not approve.

7. Has the member failed insertion of a levonorgestrel-releasing intrauterine system (IUD)?
 If yes, continue to #8 If no, do not approve.

8. Approve for 6 months.

Renewal Criteria

1. For abnormal uterine bleeding, has there been a documented response, with reduction in the days or amount of bleeding, resolution of anemia, or improvement in ability to function?

If yes, approve for 12 months.

If no, do not approve.

- c. Evidence of hemodynamic improvement such as a reduction in mPAP and PVR,
or
- d. Improvement in NYHA functional class, or
- e. Lack of functional or hemodynamic deterioration.

If yes, approve for 12 months.

If no, do not approve.

Generic Name: Ustekinumab

Brand Name: Stelara

Created: 1/22/10

Reviewed: 12/2/11, 9/12/13, 07/09/15

Updated: 1/4/17

Plaque Psoriasis

Initial criteria:

1. Does the member have active, chronic, moderate to severe Plaque Psoriasis at baseline meeting both criteria of Guideline Note 21:
 - a. Causing functional impairment (inability to use hands or feet or significant facial involvement preventing normal social interaction)
 - b. Affecting $\geq 10\%$ of the body and/or hand, foot, mucous membrane involvement
If yes, continue to #2. If no, do not approve. Does not meet Guideline Note 21.
2. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #3.
3. Has the treatment been prescribed or is it currently being supervised by a dermatologist?
If yes, continue to #4. If no, do not approve
4. Has the member tried and failed or have contraindications to Humira AND Remicade?
If yes, continue to #5. If no, do not approve
5. Is the dosing appropriate for current weight documented for the member according to product labeling?
If yes, Approve for 6 months If no, do not approve

Renewal criteria:

1. Has the member experienced a 50% improvement in affected body surface area, plaque severity and/or functioning?
If yes, continue to #2. If no, do not approve.
2. Is the dosing appropriate for current weight documented for the member according to product labeling?
If yes, Approve for 12 months If no, do not approve

Psoriatic Arthritis

Initial Criteria:

1. Does the member have an active infection or a history of recurring infections?
If yes, do not approve. If no, continue to #2.

2. Has the treatment been initiated by or is a rheumatologist or dermatologist currently supervising it?
If yes, continue to #3. If no, do not approve.
3. Does the member have psoriatic arthritis based on at least 3 out of 5 of the following?
 - Psoriasis (1 point for personal or family history, 2 points for current)
 - Psoriatic nail dystrophy
 - Negative rest result for RF
 - Dactylitis (current or history)
 - Radiological evidence of juxta-articular new bone formationIf yes, continue to #4. If no, do not approve.
4. Has the member failed or have contraindications to conventional management with **all** of the following?
 - NSAIDs, and
 - Methotrexate (or other DMARD such as leflunomide or sulfasalazine), and
 - Both of the following: Humira **and** EnbrelIf yes, continue to #5. If no, do not approve.
5. Is the dosing appropriate for the current weight documented for the member?
If yes, approve for 6 months If no, do not approve

Renewal Criteria:

1. Has the member experienced 20% or greater improvement in tender joint count and swollen joint count?
If yes, continue to #2. If no, do not approve.
2. Is the dosing appropriate for current weight documented for the member?
If yes, Approve for 12 months If no, do not approve

Note:

The combined use of Stelara and a tumor necrosis factor (TNF) inhibitor, such as Humira, Enbrel, Remicade or combined use of Stelara with Orencia is considered investigational and will not be approved.

Crohn's Disease

1. Is the request for maintenance of remission in a patient who already achieved remission with Stelara or has already initiated therapy with Stelara?
If yes, continue to renewal criteria. If no, continue to #2.
2. Is the request being initiated by or supervised by a gastroenterologist?
If yes, continue to #3. If no, do not approve.
3. Does the member have a diagnosis of severe fistulizing Crohn's disease?

If yes, continue to #9.

If no, continue to #4.

4. Does the member have moderate to severe Crohn's disease?

If yes, continue to #5.

If no, do not approve.

5. Is the request for induction of remission?

If yes, continue to #6.

If no, continue to #7.

6. Has the member failed to achieve remission with prednisone or methylprednisolone?

If yes, continue to #7.

If no, do not approve.

7. Is the member currently on steroids and considered steroid-dependent (stable disease requiring the use of steroids)?

If yes, continue to #8.

If no, do not approve.

8. Has the member tried azathioprine, 6-mercaptopurine, or methotrexate for maintenance?

If yes, continue to #9.

If no, do not approve and recommend untried agents.

9. Has the member tried and failed ALL of the following biologics?:

a. Humira; **AND**

b. Remicade; **AND**

c. Entyvio

If yes, continue to #10.

If no, deny for criteria not met

10. Approve x 6 months. Approved dosing: Stelara IV for 1 dose on Medical Benefit, then Stelara 90 mg every 8 weeks thereafter.

Renewal Criteria:

Crohn's Disease

1. Has the member experienced a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission?

If yes, approve x 1 year.

If no, do not approve.

Approved dosing: 90mg every 8 weeks.

Brand Name Varizig

Generic Name Varicella zoster immune globulin

Created: 7/11/13

Reviewed: 9/12/13

***** Nonformulary on outpatient benefit. PA required for medical benefit *****

1. Was the member diagnosed with chicken pox and the exposure occurred within the last 4 days?

If yes, continue to #2.

If no, do not approve.

2. Is the member in one of the following high risk categories?

- a. Immunocompromised children and adults
- b. Newborns of mothers with varicella before or after delivery
- c. Premature infants, neonates, and infants < 1 year
- d. Adults without evidence of immunity
- e. Pregnant woman

If yes, approve x 1 dose.

If no, do not approve.

Generic Name Vedolizumab

Brand Name Entyvio

Created: 10/30/14

Revised: 6/17/15

*****Nonformulary for outpatient benefit. PA required on medical benefit.*****

Ulcerative Colitis

Initial Criteria:

1. Does the member have a diagnosis of moderate to severe Ulcerative Colitis defined by the following criteria:
 - a. Moderate = greater than or equal to 4 stools daily.
 - b. Severe = greater than or equal to 6 bloody stools daily and evidence of toxicity such as fever, anemia, elevated ESR, or tachycardia.

If yes, continue to #2. If no, do not approve.

2. Has the member failed to achieve remission with prednisone, hydrocortisone, or methylprednisolone?

If yes, continue to #3. If no, continue to #4.

3. Has the patient failed Humira and Remicade?

If yes, continue to #5. If no, do not approve and recommend untried agents.

4. Is the request for maintenance of remission in a patient who already achieved remission with Entyvio?

If yes, continue to renewal. If no, do not approve and recommend azathioprine, 6-mercaptopurine, or sulfasalazine for maintenance.

5. Is Entyvio being initiated or supervised by a gastroenterologist?

If yes, approve x 14 weeks. If no, do not approve.

Renewal Criteria:

Ulcerative colitis

1. Has the member demonstrated a significant response including the following:
 - a. Decrease in bloody stools per day and/or
 - b. Elimination of signs of toxicity

If yes, approve for 1 year. If no, do not approve.

Initial Criteria:
Crohn's Disease

1. Does the member have a diagnosis of moderate to severe Crohn's disease? (i.e. Crohn's Disease Activity Index (CDAI) 220-450)

If yes, continue to #2.

If no, do not approve.

(Note: Moderate and Severe Disease: failed treatment for mild to moderate disease or has more prominent symptoms including fevers, significant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting (without obstructive findings), or significant anemia, evidence of intestinal obstruction, cachexia, or evidence of abscess.)

2. Is the request for induction of remission?

If yes, continue to #3.

If no, continue to #5.

3. Has the member failed to achieve remission with prednisone or methylprednisolone?

If yes, continue to #4.

If no, do not approve.

4. Has the member failed at least TWO TNF-alpha inhibitors (e.g. Humira, Remicade, Cimzia)?

5. If yes, continue to #6. If no, do not approve. Is the request for maintenance of remission in a patient who already achieved remission with Entyvio?

If yes, continue to renewal.

If no, do not approve and recommend azathioprine, 6-mercaptopurine, or methotrexate for maintenance.

6. Is Entyvio being initiated or supervised by a gastroenterologist?

If yes, approve for 14 weeks.

If no, do not approve.

Renewal Criteria:
Crohn's Disease

1. Has the member experienced a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission?

If yes, approve x 1 year.

If no, do not approve.

Generic Name Velaglucerase alfa

Brand Name Vpriv

Created: 07/15/10

Reviewed: 12/2/11, 5/21/12, 9/12/13

Revised: 5/21/12

***** Nonformulary on outpatient benefit. PA required for medical benefit *****

Initial criteria:

1. Does the member have diagnosis of type 1 Gaucher disease?
If yes, continue to #2. If no, do not approve.
2. Has the diagnosis been confirmed by one of the following?
 - a. Biochemical assay of glucocerebrosidase activity in WBCs or skin fibroblasts is less than or equal to 30% of normal activity
 - b. Genotyping revealing 2 pathogenic mutations of the glucocerebrosidase gene
If yes, continue to #3. If no, do not approve.
3. Does the severity of disease result in one or more of the following conditions:
 - a. Moderate-to-severe anemia
 - b. Thrombocytopenia with bleeding tendency
 - c. Bone disease
 - d. Significant hepatomegaly or splenomegaly
If yes, continue to #4. If no, do not approve.
4. Is the member at least 4 years old?
If yes, continue to #5. If no, do not approve.
5. Has the provider outlined objective, measurable treatment goals?
If yes, approve 6 months. If no, request from provider.
Approved dosing:
60 units/kg IV every other week.
Range 15-60 units/kg

Renewal criteria:

1. Is there any medical record documentation of stabilization of disease progression, such as:
 - a. Improvement in hematologic markers, such as increased Hgb/Hct and/or platelet counts
 - b. Reduction in spleen or liver volume
 - c. Reduction in biochemical markers, such as chitotrisidase, ACE, acid phosphatase tartrate resistant (TRAP)

- d. Reduction in skeletal markers, such as DEXA scan, bone pain, bone age (for member age 14 years or less).

If yes, approve x 6 months.

If no, do not approve.

Generic Name Voriconazole

Brand Name Vfend

Original date: 6/22/09

Reviewed: 12/2/11, 7/12/12, 9/12/13

Revised: 09/08/16

1. Is treatment being initiated by an Infectious Disease specialist?
If yes, continue to #2. If no, do not approve.
2. Does the member have a diagnosis of esophageal candidiasis or candidemia (including disseminated candidiasis)?
If yes, continue to #3. If no, continue to #4.
3. Has the member failed treatment with fluconazole?
If yes, continue to #6. If no, do not approve.
4. Does the member have a diagnosis of blastomycosis of the central nervous system and is stepping down from amphotericin B?
If yes, approve for 12 months If no, continue to # 5.
5. Does the member have a diagnosis of invasive aspergillosis or a serious infection caused by *Scedosporium apiospermum* or *Fusarium* species intolerant or refractory to other therapy?
If yes, continue to #7. If no, continue to #6.
6. Is the request for secondary prophylaxis in a member with successfully treated invasive pulmonary aspergillosis who will require subsequent immunosuppression?
If yes, approve for the duration of immunosuppression. If no, do not approve.
7. Approve for the duration of therapy.

Generic Name Zanamivir

Brand Name Relenza

Revised: 5/23/08, 3/28/13

Reviewed: 12/2/11, 7/12/12, 9/12/13

Quantity Exception Criteria:

1. Is Relenza being used for influenza treatment?
If yes, and the member has exceeded the annual quantity limit of 2 treatments or 2 inhalers which does not require a PA, forward to the pharmacist. If no, continue to #2.

2. Is Relenza being used for influenza prophylaxis (prevention)?
If yes, continue to #3. If no, do not approve.

3. Has the member been exposed to the influenza virus (household or community outbreak)?
If yes, continue to #4. If no, do not approve.

4. Does the member have any of the following that places them at high risk for developing complications?
 - a. \geq 65 years of age
 - b. Pregnancy (category C)
 - c. Children meeting the age limit or teenagers who are receiving long-term aspirin treatment and may be at risk for developing Reye's syndrome.
 - d. Chronic metabolic disease (i.e. diabetes)
 - e. Cardiovascular disease except hypertension
 - f. Weakened immune system due to HIV/AIDS, immunosuppressive medications, chemotherapy and radiation therapy.
 - g. Renal disease
 - h. Hematological disorders (i.e. anemia)
 - i. Metabolic disease such as diabetes mellitus
 - j. Any muscle or nerve condition (e.g. spinal cord injuries, seizures, or cerebral palsy) or cognitive dysfunction that can lead to difficulty breathing or swallowing and increase the aspiration risk
 - k. Residents of nursing homes or other long-term care facilities
 - l. Currently resides with or cares for high-risk people (meeting one of the above criteria)If yes, continue to #5. If no, do not approve.

5. Does the member have chronic pulmonary disease (COPD/asthma)?
If yes, do not approve If no, continue to #6.

6. Approve with the following duration:

- a. 10 day therapy for household or community outbreaks.
- b. 30 days for institutional outbreaks. If an extension needed then the provider needs to submit another prior authorization request.

Utilization Management (UM) Coded Edits

The following are criteria for drugs that are coded on formulary with restrictions that allow some claims to PA without prior authorization if certain limits (such as age, previous drug failures) are able to be identified within the pharmacy claim history. Claims that do not pay are held to the following PA criteria:

Created: 7/19/16

Actonel (risedronate)

1. Has the member tried and failed alendronate?
If yes, approve x life. If no, deny for not meeting ST.

Diagnosis-inferred coded Antifungals (Miconazole, Nystatin Bulk Powder, Nystatin Oral, Nystatin-TCA combo)

1. Does the member have a comorbid condition which makes them immunocompromised (such as history of RA, Psoriasis, active cancer, diabetes or HIV)?
If yes, approve x life. If no, continue to #2
2. Is the member's condition funded under OHP?
If yes, approve. If no, deny.

Budesonide (Pulmicort) Nebulizer Solution:

1. Is the member age 6 or less?
If yes, approve until age 7. If no, continue to #2.
2. Is the rationale for avoiding inhalers based on technique difficulties?
If yes, continue to #3. If no, continue to #4.
3. Has the member tried and failed the use of a spacer-device?
If yes, approve x life. If no, deny for criteria not met.
4. Does the member have a documented reason inhaled corticosteroid steroid inhalers cannot be used (include severe/end stage COPD)?
If yes, approve x life. If no, deny for criteria not met.

Caffeine Citrate

1. Is the member age 1 or less?
If yes, approve until age 1. If no, deny.

First-Omeprazole

1. What is the member's age?

Ages 0 – 6 years: Approve until age 7.
Ages 7-18 year: Continue to #5
Ages 19 and up: Continue to #2

2. Is the diagnosis GERD?
If yes, continue to #3. If no, continue to #4.

3. Does the request meet at least ONE of the following?
 - a) Continuation of PPI therapy beyond 8 weeks (including other PPIs)?**Or**
 - b) The request is for more than 8 weeks or unspecified duration?
If yes, deny. Chronic GERD Therapy If no, continue to #5
Not Covered per Guideline Note #144

4. Does the member have a documented and medically appropriate diagnosis which is currently funded by the Oregon Health Plan (OHP) Prioritized List?
If yes, continue to #5. If no, deny for BTL.

5. Has the member tried and failed one of each of the following:
 - a. cimetidine liquid or ranitidine syrup **AND**
 - b. omeprazole capsules (either swallowed whole or compounded into a suspension). If the member's pharmacy refuses to compound based on interpretation of FDA ban on compounding "available products", please consider this ground for not using compound if swallowing whole capsules is not medically an option.If yes, approve as follows: If no, deny for criteria not met.
Ages 7-18 year: Approve until age 19
Ages 19 & up **AND** not GERD: Evaluated for medical necessity for duration .
Ages 19 & up for GERD: 8 weeks

Fluoride Products (not containing other vitamins or minerals)

1. Is the members age less than 19?
If yes, approve until age 19. If no, deny for OHP exclusion.
OHP does not cover fluoride supplements for adults.

Griseofulvin Suspension

1. Is the member less than the age of 7?
If yes, approve until age 7. If no, continue to #2.

2. Evaluate for whether condition meets ALL of the following:
 - a) funded by the Prioritized list **AND**
 - b) is an appropriate treatment choice for the indication **AND**
 - c) there is no untried alternative covered on formulary without PA required (such as, but not limited to, terbinafine or fluconazole-available as a suspension without PA).

If yes, approve for appropriate treatment duration If no, deny.

Liquid products with age limit to allow for kids:

Suspension/Solution Products with age max of 6:

Clindamycin, methylphenidate, nizatidine, propranolol, Trileptal, Vibramycin, Viread

Suspension/Solution Products with age max of 8:

Tamiflu

1. Is the request for Tamiflu Suspension?

If yes, continue to #2.

If no, continue to #3.

2. Is the member less than the age of 9?

If yes, approve until age 9.

If no, continue to #4

3. Is the member less than the age of 7?

If yes, approve until age of 7.

If no, continue to #4

4. Is there documentation that both of the following are met:

a) documentation the member is unable to take solid dosage forms?

b) the use is for a funded OHP condition by the prioritized list and is medically necessary/appropriate?

If yes, approve x max 12 months

If no, deny for criteria not met and offer solid dosage form.

Long Acting Stimulants

Products: Generics of: Concerta, Ritalin LA, Metadate CD, Adderall XR.

1. Is the member less than age 19?

If yes, approve until age 19.

If no, continue to #2.

2. Has the member tried and failed one of each of the following (note: compliance/convenience concerns do not satisfy failure):

a. methylphenidate IR or dexamethylphenidate IR

b. generic Adderall IR or dextroamphetamine IR

If yes, approve for life.

If no, continue to #3.

3. Does the member have a history of stimulant abuse AND the provider states it would be inappropriate to use immediate release stimulants?

If yes, continue to #4.

If no, deny for criteria not met.

4. Has the member tried and failed BOTH of the following non-stimulant alternatives:

a. Strattera (covered directly by the State) **and**

b. bupropion (covered directly by the State)

If yes, approve x life.

If no, deny for criteria not met.

Formulary Multivitamins

1. Which type of multivitamin product is requested?
 - a. Pre-natal: See separate Prenatal PA Criteria
 - b. Combination with fluoride: continue to #2.
 - c. Other (no fluoride, not prenatal): continue to #3

2. Is the member under the age of 3?
If yes, approve until age of 3

If no, deny for not FDA approved. For kids age less than 19, fluoride products alone covered.

3. Does the member have a documented vitamin-deficiency requiring multivitamin supplementation?
If yes, approve as long as deficiency is expected to last.

If no, deny for not FDA approved.

Formulary Prenatal Vitamins:

1. Does the member meet both of the following?
 - a. Female Gender AND
 - b. Age less than 50.If yes, approve until age 50.

If no, continue to #2.

2. Does the member have a documented vitamin-deficiency requiring multi-vitamin supplementation?
If yes, approve as long as deficiency is expected to last.

If no, deny

Vaccines:

Products: Any vaccine WITHOUT its own unique criteria.

1. Is the product coverable by the Vaccine-For-Children (VFC) Program?
If yes, continue to #2.

If no, continue to #3.

2. If the member age less than 19?
If yes, deny and notify of VFC coverage through doctor's office/clinic.

If no, continue to #3.

3. Is the use (particularly member's age) in accordance with CDC/ACIP vaccine recommendations?
If yes, approve.

If no, deny for not medically necessary/appropriate.

Viramune XR 100 mg:

1. Is the member less than 19 years of age?

If yes, approve until age 19.

If no, deny. FDA label recommends higher dosages in adults.